US20110044979A1 - Domain antibody construct - Google Patents

Domain antibody construct Download PDF

Info

Publication number
US20110044979A1
US20110044979A1 US12/831,874 US83187410A US2011044979A1 US 20110044979 A1 US20110044979 A1 US 20110044979A1 US 83187410 A US83187410 A US 83187410A US 2011044979 A1 US2011044979 A1 US 2011044979A1
Authority
US
United States
Prior art keywords
seq
domain antibody
antibody construct
sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/831,874
Inventor
Anthony G. Doyle
Benjamin P. Woolven
Ian M. Tomlinson
Jennifer A. Lee
Philip A. Jennings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006900456A external-priority patent/AU2006900456A0/en
Application filed by Individual filed Critical Individual
Priority to US12/831,874 priority Critical patent/US20110044979A1/en
Assigned to DOMANTIS LIMITED reassignment DOMANTIS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEE, JENNIFER A., TOMLINSON, IAN M., WOOLVEN, BENJAMIN P.
Assigned to PEPTECH LIMITED reassignment PEPTECH LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOYLE, ANTHONY G., JENNINGS, PHILIP A.
Assigned to ARANA THERAPEUTICS LIMITED reassignment ARANA THERAPEUTICS LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PEPTECH LIMITED
Assigned to ARANA THERAPEUTICS PTY LTD reassignment ARANA THERAPEUTICS PTY LTD CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ARANA THERAPEUTICS LIMITED
Assigned to CEPHALON AUSTRALIA PTY LTD reassignment CEPHALON AUSTRALIA PTY LTD CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ARANA THERAPEUTICS PTY LTD
Assigned to PEPTECH LIMITED reassignment PEPTECH LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOMANTIS LIMITED
Publication of US20110044979A1 publication Critical patent/US20110044979A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/164Retinal disorders, e.g. retinopathy

Definitions

  • the present invention relates to a domain antibody construct useful for human therapy. More particularly, the present invention relates to a domain antibody construct which binds to human TNF- ⁇ and its use in the treatment of disorders characterised by TNF- ⁇ activity.
  • Tumor necrosis factor alpha is a cytokine that has been implicated in mediating shock and the pathophysiology of a variety of human diseases and disorders including sepsis, infections, autoimmune diseases eg. rheumatoid arthritis, Crohn's disease, ulcerative colitis and other bowel conditions, psoriasis, toxic shock, transplant rejection and graft-versus-host disease.
  • TNF- ⁇ is produced primarily by activated macrophages and T lymphocytes, but also by neutrophils, endothelial cells, keratinocytes and fibroblasts during acute inflammatory reactions.
  • TNF- ⁇ Because of its role in inflammation, TNF- ⁇ has emerged as an important target for inhibition in efforts to reduce the symptoms of inflammatory disorders.
  • Various approaches to inhibition of TNF- ⁇ for the clinical treatment of disease have been pursued, including particularly the use of soluble TNF- ⁇ receptors and antibodies specific for TNF- ⁇ .
  • Domain antibodies are the smallest functioning binding units of antibodies and correspond to the variable regions of either the heavy (V H ) or light (V L ) chains of antibodies. Domain antibodies have a molecular weight of approximately 13 kDa, or less than one tenth the size of a full antibody.
  • domain antibodies are well expressed in bacterial, yeast and mammalian systems. Their small size allows for higher molar quantities per gram of product, thus providing a significant increase in potency per milligram dose.
  • dAbs can be used as building blocks to create therapeutic products such as multiple targeting dAb-containing molecules in which two or more dAbs bind to two or more distinct molecular targets, or dAbs may be incorporated into structures designed for pulmonary or oral administration.
  • the present inventors have now devised a novel domain antibody construct comprising an immunoglobulin variable domain linked to a constant region including a truncated C H 1 domain. It is postulated that the inclusion of a constant region will assist in prolonging the in vivo half-life of the dAb which is typically of a short duration.
  • New World primates are sufficiently similar to human to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primate-derived antibodies are introduced into a human.
  • New World primates comprise at least 53 species commonly divided into two families, the Callithricidae and Cebidae.
  • the Callithricidae consist of marmosets and tamarins.
  • the Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, night or owl monkey and the howler monkey.
  • the present invention provides a domain antibody construct which binds to human TNF- ⁇ , the construct comprising:
  • said modified hinge region sequence contains either a deletion or a single amino acid substitution of the cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
  • the present invention provides a nucleic acid sequence encoding the domain antibody construct of the first aspect of the invention.
  • the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF- ⁇ , wherein the nucleic acid molecule comprises a nucleic acid sequence at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:50 or SEQ ID No:51 and most preferably, the sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF- ⁇ , wherein the nucleic acid molecule comprises a nucleic acid sequence which hybridises under conditions of high stringency to the nucleotide sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • the invention provides a pharmaceutical composition comprising an effective amount of the domain antibody construct according to the first aspect, together with a pharmaceutically acceptable carrier or diluent.
  • the present invention provides for the use of the domain antibody construct according to the first aspect of the invention in a diagnostic application for detecting human TNF- ⁇ .
  • the invention provides a method for treating a disorder characterised by human TNF- ⁇ activity in a human subject, comprising administering to the subject a pharmaceutical composition according to the fifth aspect of the invention.
  • FIG. 1 shows the amino acid (SEQ ID No:5) and nucleotide sequence (SEQ ID No:6) of the acceptor dAb.
  • FIG. 2 shows the structure of the preferred embodiment of the domain antibody construct according to the present invention as (A) a monomer and (B) a dimer.
  • FIG. 3(A-G) shows the nucleotide and amino acid sequences of eleven (11) marmoset and six (6) Owl monkey V ⁇ gene segments.
  • FIG. 4 shows the acceptor dAb amino acid (SEQ ID NO:5) and nucleotide sequence (both strands) (SEQ ID NO:6 AND SEQ ID NO:68).
  • the restriction digest sites for Kpn I and San DI which excises region including the CDR2 is indicated in the figure.
  • CDR2 residues removed are indicated in underlined.
  • FIG. 5 shows the ability of Compound 170 (SEQ ID No:11) to neutralise TNF- ⁇ mediated cytotoxicity in a murine L929 cell viability assay.
  • FIG. 6 shows that Compound 170 (SEQ ID No:11) prevents the interaction of TNF- ⁇ with the human p55 or p75 TNF receptors.
  • FIG. 7 shows Compound 170 (SEQ ID No:11) staining of transmembrane TNF- ⁇ -expressing NS0 27D4 cells (solid black line) shows higher fluorescence intensity than irrelevant specificity isotype-matched control (grey fill).
  • FIG. 8 shows Compound 170 (SEQ ID No:11) produced in a bacterial expression system retained binding to TNF- ⁇ in an ELISA.
  • FIG. 9 shows the efficacy of Compound 170 (SEQ ID No:11) in a TNF-mediated murine arthritis model relative to specificity control human IgG 1 .
  • mice were scored (arthritic score), (A), and weighed, (B).
  • FIG. 10 shows the effect on protein expression of Compound 112 (SEQ ID No:59) and Compound 170 (SEQ ID No:11).
  • the present inventors have generated a domain antibody construct which binds to human TNF- ⁇ and which is postulated to exhibit low immunogenicity when administered to humans.
  • the domain antibody construct comprises a portion corresponding to a variable domain of an immunoglobulin heavy or light chain (ie. a domain antibody (dAb)), a hinge region and a portion corresponding to a constant region of an antibody heavy chain but wherein the constant region has a truncated C H 1 domain.
  • dAb domain antibody
  • constant region portion is postulated to increase the in vivo half life of the dAb as well as providing effector functions which are believed to be a component of the anti-inflammatory mechanism of anti-TNF antibodies.
  • the present invention provides a domain antibody construct which binds to human TNF- ⁇ , the construct comprising:
  • said modified hinge region sequence contains either a deletion or a single amino acid substitution of the cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
  • sequence of the C H 1 domain and the hinge region is XEPKSZDKTHTCPPCPA (SEQ ID NO:64) wherein X is valine, leucine or isoleucine and Z is absent or an amino acid other than cysteine. It is preferred that X at position one is valine and Z is serine.
  • the dAb comprises an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate wherein the CDR is selected from the group consisting of AATKLQS (SEQ ID No:1), EASSLQS (SEQ ID No:2), EASKLQS (SEQ ID No:3), and SASNLET (SEQ ID No:4)
  • CDR complementarity determining region
  • the CDR is CDR2.
  • the constant region comprises C H 2 and C H 3 domains which together have the following sequence:
  • the domain antibody construct comprises an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:11, and most preferably the sequence set forth in SEQ ID No:11.
  • binding to is intended to refer to the binding of an antigen by an immunoglobulin variable region with a dissociation constant (K d ) of 1 ⁇ M or lower as measured by surface plasmon resonance analysis using, for example a BIAcoreTM surface plasmon resonance system and BIAcoreTM kinetic evaluation software (eg. version 2.1).
  • K d dissociation constant
  • the affinity or dissociation constant (K d ) for a specific binding interaction is preferably about 500 nM or lower, more preferably about 300 nM or lower and preferably at least 300 nM to 50 pM, 200 nM to 50 pM, and more preferably at least 100 nM to 50 pM, 75 nM to 50 pM, 10 nM to 50 pM.
  • dAb refers to an antibody single variable domain (V H or V L ) polypeptide that specifically binds antigen.
  • the domain antibody construct forms a homo- or heterodimer with another domain antibody construct according to the present invention. Dimerisation can increase the strength of antigen binding, wherein the strength of binding is related to the sum of the binding affinities of the multiple binding sites.
  • the hinge region of the domain antibody construct comprises at least one, and preferably two, cysteine residues.
  • the domain antibody construct forms a homodimer with an identical domain antibody construct.
  • the present invention provides a dimeric domain antibody construct which binds to human TNF- ⁇ wherein the dimer consists of two domain antibody constructs according to the present invention.
  • the dimeric domain antibody construct is a homodimer and it is particularly preferred that the domain antibody constructs making up the homodimer comprise an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:11, and most preferably the sequence set forth in SEQ ID No:11.
  • the present invention provides a nucleic acid sequence encoding the domain antibody construct of the first aspect of the invention.
  • the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF- ⁇ , wherein the nucleic acid molecule comprises a nucleic acid sequence at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:50 or SEQ ID No:51 and most preferably, the sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF- ⁇ , wherein the nucleic acid molecule comprises a nucleic acid sequence which hybridises under conditions of high stringency to the nucleotide sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • amino acid sequence identities or similarities may be calculated using the GAP programme and/or aligned using the PILEUP programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America (Devereaux et al, 1984).
  • the GAP programme utilizes the algorithm of Needleman and Wunsch (1970) to maximise the number of identical/similar residues and to minimise the number and length of sequence gaps in the alignment.
  • the Clustal W programme of Thompson et al, (1994) is used.
  • nucleotide sequences may be aligned and their identity calculated using the BESTFIT programme or other appropriate programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America (Devereaux et al, Nucl. Acids Res., 12:387-395, 1984).
  • the invention is further based on a method for amplification of New World primate immunoglobulin variable region genes, for example by polymerase chain reaction (PCR) from nucleic acid extracted from New World primate lymphocytes using primers specific for heavy and light chain variable region gene families.
  • PCR polymerase chain reaction
  • information regarding the boundaries of the variable domains of heavy and light chain genes can be used to design PCR primers that amplify the variable domain from a cloned heavy or light chain coding sequence encoding an antibody known to bind a given antigen.
  • the amplified variable region is then inserted either alone or as a fusion with another polypeptide sequence for the human or primate constant region sequence of the invention into a suitable expression vector for production of the domain antibody construct of the invention.
  • suitable expression vectors will be familiar to those skilled in the art.
  • the repertoire of V H , V L and constant region domains can be a naturally occurring repertoire of immunoglobulin sequences or a synthetic repertoire.
  • a naturally occurring repertoire is one prepared, for example, from immunoglobulin-expressing cells harvested from one or more primates. Such repertoires can be na ⁇ ve ie. prepared from newborn immunoglobulin expressing cells, or rearranged ie. prepared from, for example, adult primate B cells. If desired, clones identified from a natural repertoire, or any repertoire that bind the target antigen are then subject to mutagenesis and further screening in order to produce and select variants with improved binding characteristics.
  • Synthetic repertoires of single immunoglobulin variable domains are prepared by artificially introducing diversity into a cloned variable domain.
  • a repertoire of V H and V L domains can be screened for desired binding specificity and functional behaviour by, for example phage display.
  • Methods for the construction of bacteriophage display libraries and lambda phage expression libraries are well known in the art.
  • the phage display technique has been described extensively in the art and examples of methods and compounds for generating and screening such libraries and affinity maturing the products of them can be found in, for example, Barbas et al. (1991) PNAS 88:7978-7982; Clarkson et al. (1991) Nature 352:624-628; Dower et al. PCT. 91/17271, U.S. Pat. No. 5,427,908, U.S. Pat. No.
  • Recombinant libraries expressing the repertoire of V H and V L domains can be expressed on the surface of microorganisms eg. yeast or bacteria (see PCT publications WO 99/36569 and 98/49286).
  • the domain antibody construct of the invention may be produced by recombinant means, including from eukaryotic expression systems including, for example, yeast, higher plant, insect and mammalian cells, as well as fungi and virally-encoded expression systems, as described herein or as known in the art.
  • eukaryotic expression systems including, for example, yeast, higher plant, insect and mammalian cells, as well as fungi and virally-encoded expression systems, as described herein or as known in the art.
  • the domain antibody constructs of the present invention can be prepared using an S antibody encoding nucleic acid to provide transgenic plants and cultured plant cells (e.g., but not limited to tobacco and maize) that produce such constructs in the plant parts or in cells cultured therefrom.
  • transgenic tobacco leaves expressing recombinant proteins have been successfully used to provide large amounts of recombinant proteins, e.g., using an inducible promoter (see, e.g., Cramer et al., Curr. Top. Microbol. Immunol. 240:95-118 1999) and references cited therein.
  • transgenic maize has been used to express mammalian proteins at commercial production levels, with biological activities equivalent to those produced in other recombinant systems or purified from natural sources (see, e.g., Hood et al., Adv. Exp. Med. Biol. 464:127-147 1999 and references cited therein).
  • Antibodies have also been produced in large amounts from transgenic plant seeds including antibody fragments, such as single chain antibodies (scFv's), including tobacco seeds and potato tubers (see, e.g., Conrad et al., Plant Mol. Biol. 38:101-109 1998 and reference cited therein).
  • the domain antibody constructs of the present invention can also be produced using transgenic plants, according to known methods (see also, e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99-108 October, 1999: Ma & Hein., Trends Biotechnol. 13:522-7 1995; Ma et al., Plant Physiol. 109:341-6 1995; Whitelam et al., Biochem. Soc. Trans. 22:940-944 1994; and references cited therein; each of the above references is entirely incorporated herein by reference).
  • the domain antibody constructs of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a eukaryotic host, including, for example, yeast, higher plant, insect and mammalian cells.
  • a eukaryotic host including, for example, yeast, higher plant, insect and mammalian cells.
  • the antibody constructs of the present invention can be glycosylated or can be non-glycosylated, with glycosylated preferred.
  • Such methods are described in many standard laboratory manuals Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2 nd Edition, Cold Spring Harbor, N.Y. 1989, Sections 17.37-17.42; Ausubel et al, eds.
  • the recombinant peptide/protein library is displayed on ribosomes (for examples see Roberts, R W and Szostak, J. W. 1997 Proc. Natl. Acad. Sci. USA. 94:12297-123202 and PCT Publication No. WO98/31700).
  • a DNA library eg of antibodies or derivatives preferably prepared from immunised cells, but not so limited
  • translation of the library such that the protein and “immunised” mRNAs stay on the ribosome
  • affinity selection eg by binding to RSP
  • mRNA isolation eg by polymerase chain reaction or related technology
  • Remplification eg by polymerase chain reaction or related technology. Additional rounds of selection and amplification can be coupled as necessary to affinity maturation through introduction of somatic mutation in this system or by other methods of affinity maturation as known in the state of the art.
  • the CDR sequences may be obtained from several sources, for example, databases such as The National Centre for Biotechnology Information protein and nucleotide databases www.ncbi.nlm.nih.gov, The Kabat Database of Sequences of Proteins of Immunological Interest www.kabatdatabase.com, or the IMGT database www.imgt.cines.fr.
  • the CDR regions can be predicted from the V H and V L domain repertoire (see for example Kabat E A and Wu T T Attempts to locate complementarity determining residues in the variable positions of light and heavy chains. Ann. NY Acad. Sci. 190:382-393 (1971)).
  • the CDR sequence may be a genomic DNA or a cDNA.
  • the preferred method of the present invention involves replacement of the CDR2 in the variable region (or dAb) via primer directed mutagenesis.
  • This method consists of annealing a synthetic oligonucleotide encoding a desired mutation(s) to a target region where it serves as a primer for initiation of DNA synthesis in vitro, extending the oligonucleotide by a DNA polymerase to generate a double-stranded DNA that carries the desired mutation, and ligating and cloning the sequence into an appropriate expression vector.
  • the New World primate CDR sequence is grafted into a variable region sequence which is of low immunogenicity in humans.
  • domain antibody construct or antigen-binding portion thereof, does not raise an antibody response in a human of sufficient magnitude to reduce the effectiveness of continued administration of the domain antibody construct for a sufficient time to achieve therapeutic efficacy.
  • variable region sequence into which the New World primate CDR is grafted is the “dAb acceptor sequence” (designated Compound 128), in FIG. 1 .
  • the dAb acceptor sequence consists of the amino acid sequence set forth in SEQ ID No:5:
  • a marmoset New World primate CDR sequence SASNLET (SEQ ID No:4) is grafted into the variable region dAb acceptor sequence so as to replace the CDR2 sequence (SASELQS; SEQ ID No:55) of the dAb acceptor sequence to produce the following dAb (designated Compound 145):
  • the dAb of the domain antibody construct which binds to human TNF- ⁇ comprises the amino acid sequence set forth in SEQ ID No:7.
  • variable region sequence (dAb) of the domain antibody construct may be further subject to affinity maturation in order to improve its antigen binding characteristics. This may necessitate the modification of certain amino acid residues within CDR1, CDR3 or framework of the domain antibody construct.
  • variable region (dAb) of the domain antibody construct which binds to human TNF- ⁇ comprises the amino acid sequence of SEQ ID No:8 or SEQ ID No:9. These have been designated Compound 123 and Compound 100 respectively, and their sequences are shown below:
  • variable region (dAb) of the domain antibody construct which binds to human TNF- ⁇ comprises the amino acid sequence of SEQ ID No:10. This has been designated Compound 196 and the sequence is provided below:
  • the constant region sequence of the domain antibody construct may be derived from human or primate sequences.
  • the primate sequence may be New World primate or an Old World primate sequence.
  • Suitable Old World primates include chimpanzee, or other hominid ape eg. gorilla or orangutan, which because of their close phylogenetic proximity to humans, share a high degree of homology with the human constant region sequence.
  • the constant region is derived from a human antibody sequence.
  • the inventors have truncated the C H 1 domain of the constant (Fc) region.
  • a minimal number of C H 1 domain residues have been retained in order to provide flexibility in the domain antibody construct around the hinge region.
  • at least 20 C-terminal amino acid residues of the C H 1 domain are retained, more preferably at least 10 amino acids, still more preferably at least 5 amino acids, even more preferably a single amino acid residue.
  • the domain antibody construct has a format comprising dAb-C terminal C H 1 domain residue-hinge region-C H 2 domain-C H 3 domain as illustrated schematically in FIG. 2 .
  • the domain antibody construct has the amino acid sequence set forth in SEQ ID No:11. This has been designated Compound 170.
  • the hinge region of the naturally occurring immunoglobulin contains a cysteine (C) side chain which facilitates the formation of a disulfide bond between the C H 1 domain of the heavy chain and the constant domain of the light chain.
  • C cysteine
  • the construct comprises only a single variable domain and thus leaves a potentially reactive unpaired cysteine residue, the cysteine residue has been substituted with an amino acid residue which prevents disulfide bond formation.
  • the potential consequences of having an unpaired cysteine may include reduced protein expression due to aggregation and misfolding of the construct.
  • any hinge region sequence derived from any of the antibody classes would be appropriate for use in the present invention. It is preferred however, that the hinge region is derived from the antibody subclass IgG i . Preferably, the hinge region is based on the naturally occurring sequence of the hinge region of IgG i and comprises the sequence EPKS S DKTHTCPPCPA (SEQ ID No:12). In this sequence, the Cys which normally occurs at position 5 is replaced by the underlined bolded Ser residue.
  • the C-terminal amino acid residue of the C H 1 domain is derived from IgG1. More preferably, the C H 1 residue is a valine (V) residue or a conservative amino acid substitution such as leucine (L) or isoleucine (I). This residue is located immediately proximal to the hinge region and assists in increasing the flexibility of the construct around the hinge region.
  • V valine
  • I isoleucine
  • the domain antibody construct may be derivatised or linked to another functional molecule.
  • the domain antibody construct can be functionally linked by chemical coupling, genetic fusion, noncovalent association or otherwise, to one or more other molecular entities, such as another antibody, a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody-binding portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • Useful detectable agents with which the domain antibody construct may be derivatised include fluorescent compounds.
  • Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin and the like.
  • the domain antibody construct may also be derivatised with detectable enzymes such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When the domain antibody construct is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product.
  • the domain antibody construct may also be derivatised with biotin, and detected through indirect measurement of avidin or streptavidin binding.
  • the domain antibody construct according to the invention may be linked to one or more molecules which provide increased half-life and resistance to degradation without loss in activity (eg binding affinity) in vivo. These molecules may be linked to the domain antibody construct via a linker so that they do not interfere/sterically hinder the antigen binding site.
  • adduct molecules include for example dAbs directed to an endogenous molecule as described in US patent application 20050271663. Typically, such adduct molecules are polypeptides or fragments of polypeptides which occur naturally in vivo and which resist degradation or removal by endogenous mechanisms. Molecules which increase half life may be selected from the following:
  • proteins from the extracellular matrix eg. collagen, laminin, integrin and fibronectin
  • proteins found in blood eg. fibrin ⁇ -2 macroglobulin, serum albumin, fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, protein, ubiquitin, uteroglobulin, ⁇ -2 microglobulin, plasminogen, lysozyme, cystatin C, alpha-1-antitrypsin and pancreatic kypsin inhibitor
  • immune serum proteins eg. IgE, IgG, IgM
  • transport proteins eg.
  • retinol binding protein ⁇ -1 microglobulin
  • defensins eg. beta-defensin 1, neutrophil defensins 1, 2 and 3
  • proteins found at the blood brain barrier or in neural tissues eg. melanocortin receptor, myelin, ascorbate transporter
  • transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins see U.S. Pat. No.
  • brain capillary endothelial cell receptor transferrin, transferrin receptor, insulin, insulin-like growth factor 1 (IGF 1) receptor, insulin-like growth factor 2 (IGF 2) receptor, insulin receptor;
  • IGF 1 insulin-like growth factor 1
  • IGF 2 insulin-like growth factor 2
  • proteins localised to the kidney eg. polycystin, type IV collagen, organic anion transporter K1, Heymann's antigen
  • proteins localised to the liver eg. alcohol dehydrogenase, G250
  • blood coagulation factor X blood coagulation factor X
  • ⁇ -1 antitrypsin ⁇ -1 antitrypsin
  • proteins localised to the lung eg. secretory component (binds IgA);
  • proteins localised to the heart eg. HSP 27;
  • proteins localised to the skin eg. keratin;
  • bone specific proteins such as bone morphogenic proteins (BMPs) eg. BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-1) and -8 (OP-2);
  • tumour specific proteins eg. human trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins eg cathepsin B (found in liver and spleen);
  • disease-specific proteins eg.
  • LAG-3 lymphocyte activation gene
  • osteoprotegerin ligand OPGL
  • OX40 a member of the TNF receptor family, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human T cell leukaemia virus type-I (HTLV-I)-producing cells—see Pankow R et al J. Immunol.
  • metalloproteases associated with arthritis/cancers
  • metalloproteases including CG6512 Drosophila , human paraplegin, human FtsH, human AFG3L2, murine ftsH
  • angiogenic growth factors including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), transforming growth factor- ⁇ (TGF- ⁇ ), tumor necrosis factor-alpha (TNF- ⁇ ), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet derived endothelial growth factor (PD-ECGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BB (PDGF), fractalkine; (s) stress proteins (heat shock proteins); and (t) proteins involved in Fc transport.
  • FGF-1 acidic fibroblast growth factor
  • FGF-2 basic fibroblast growth factor
  • the present invention also extends to a PEGylated domain antibody construct which provides increased half-life and resistance to degradation without a loss in activity (e.g. binding affinity) relative to non-PEGylated antibody polypeptides.
  • the domain antibody construct can be coupled, using methods known in the art, to polymer molecules (preferably PEG) useful for achieving the increased half-life and degradation resistance properties.
  • Polymer moieties which can be utilised in the invention can be synthetic or naturally occurring and include, but not limited to straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide such as a homo- or heteropolysaccharide.
  • Preferred examples of synthetic polymers which can be used in the invention include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly(vinyl alcohol) and derivatives or substituted forms thereof.
  • Particularly preferred substituted polymers for linkage to the domain antibody construct include substituted PEG, including methoxy(polyethylene glycol).
  • Naturally occurring polymer moieties which can be used in addition to or in place of PEG include lactose, amylose, dextran, or glycogen, as well as derivatives thereof which would be recognised by persons skilled in the art.
  • the polymer (PEG) molecules useful in the invention can be attached to the domain antibody construct using methods which are well known in the art.
  • the first step in the attachment of PEG or other polymer moieties to the domain antibody construct of the invention is the substitution of the hydroxyl end-groups of the PEG polymer by electrophile-containing functional groups.
  • PEG polymers are attached to either cysteine or lysine residues present in the domain antibody construct monomers or multimers.
  • the cysteine and lysine residues can be naturally occurring, or can be engineered into the domain antibody construct molecule.
  • Pegylation of the domain antibody constructs of the invention may be accomplished by any number of means (see for example Kozlowski-A & Harris-J M (2001) Journal of Controlled Release 72:217).
  • PEG may be attached to the domain antibody construct either directly or by an intervening linker.
  • Linkerless systems for attaching polyethylene glycol to proteins is described in Delgado et al., (1992), Crit. Rev. Thera. Drug Carrier Sys. 9:249-304; Francis et al., (1998), Intern. J. Hematol. 68:1-18; U.S. Pat. No. 4,002,531; U.S. Pat. No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.
  • One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monomethoxy polyethylene glycol (MPEG) using tresylchloride. Following reaction of amino acid residues with tresylated MPEG, polyethylene glycol is directly attached to the amine groups.
  • MPEG monomethoxy polyethylene glycol
  • the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.
  • Polyethylene glycol can also be attached to proteins using a number of different intervening linkers.
  • U.S. Pat. No. 5,612,460 discloses urethane linkers for connecting polyethylene glycol to proteins.
  • Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1′-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives.
  • MPEG-succinimidylsuccinate MPEG activated with 1,1′-carbonyldiimidazole
  • MPEG-2,4,5-trichloropenylcarbonate MPEG-p-nitrophenolcarbonate
  • MPEG-succinate derivatives A number of additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins
  • the domain antibody construct is coupled directly to polyethylene glycol via a lysine residue.
  • the domain antibody construct is coupled directly to PEG via a cysteine residue.
  • the unpaired cysteine residue could pre-exist in the sequence, could be added by incorporating a cysteine residue in, for example, the C-terminus of the domain antibody construct.
  • attachment of the PEG to the domain antibody construct could be facilitated via a disulphide bonded cysteine such as that described in US20060210526.
  • polymer molecules include, for example, derivatives which have additional moieties or reactive groups present therein to permit interaction with amino acid residues of the domain antibody constructs described herein.
  • derivatives include N-hydroxylsuccinimide (NHS) active esters, succinimidyl propionate polymers, and sulfhydryl-selective reactive agents such as maleimide, vinyl sulfone, and thiol.
  • NHS N-hydroxylsuccinimide
  • PEG polymers can be linear molecules, or can be branched wherein multiple PEG moieties are present in a single polymer.
  • the reactive group (e.g., MAL, NHS, SPA, VS, or Thiol) may be attached directly to the PEG polymer or may be attached to PEG via a linker molecule.
  • the size of polymers useful in the invention can be in the range of 500 Da to 60 kDa, for example, between 1000 Da and 60 kDa, 10 kDa and 60 kDa, 20 kDa and 60 kDa, 30 kDa and 60 kDa, 40 kDa and 60 kDa, and up to between 50 kDa and 60 kDa.
  • the polymers used in the invention, particularly PEG can be straight chain polymers or may possess a branched conformation.
  • the domain antibody construct according to the first aspect may be multimerised, as for example, hetero- or homodimers, hetero- or homotrimers, hetero- or homotetramers, or higher order hetero- or homomultimers. Multimerisation can increase the strength of antigen binding, wherein the strength of binding is related to the sum of the binding affinities of the multiple binding sites.
  • the invention provides a pharmaceutical composition comprising an effective amount of the domain antibody construct according to the first aspect, together with a pharmaceutically acceptable carrier or diluent.
  • a “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like which are physiologically compatible.
  • pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like as well as combinations thereof.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
  • Pharmaceutically acceptable substances such as minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers.
  • the composition may be in a variety of forms, including liquid, semi-solid and solid dosage forms, such as liquid solutions (eg inhalable, injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
  • liquid solutions eg inhalable, injectable and infusible solutions
  • dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
  • the composition is in the form of an injectable solution for immunization.
  • the administration may be intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular.
  • compositions typically must be sterile and stable under the conditions of manufacture and storage.
  • the compositions can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.
  • the proper fluidity of a solution can be maintained by for example, use of a coating such as lecithin and/or surfactants.
  • Sterile injectable solutions can be prepared by incorporating the active compound (ie. domain antibody construct) in the required amount into an appropriate solvent with one or a combination of ingredients listed above, followed by filtered sterilisation.
  • composition may also be formulated as a sterile powder for the preparation of sterile injectable solutions.
  • the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • Compatible polymers may be used such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid.
  • composition may also be formulated for oral administration.
  • the domain antibody construct may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
  • Formulations that allow for pulmonary, rectal, transdermal, intrathecal and intraocular administration will be familiar to persons skilled in the art.
  • the domain antibody construct may be co-formulated with and/or co-administered with one or more additional therapeutic agents eg. soluble TNF- ⁇ receptor or a chemical agent that inhibits human TNF- ⁇ production, or antibodies that bind other targets such as cytokines or cell surface molecules. Alternatively, it may be co-administered with a soluble immunochemical reagent such as protein A, C, G or L.
  • additional therapeutic agents eg. soluble TNF- ⁇ receptor or a chemical agent that inhibits human TNF- ⁇ production, or antibodies that bind other targets such as cytokines or cell surface molecules.
  • a soluble immunochemical reagent such as protein A, C, G or L.
  • An effective amount may include a therapeutically effective amount or prophylactically effective amount of the domain antibody construct of the invention.
  • a therapeutically effective amount refers to an amount effective at dosages and for periods of time necessary, to achieve the desired therapeutic result.
  • a prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Because a prophylactic dose is administered to a subject prior to or at an earlier stage of disease, the prophylactically effective amount may be less than the therapeutically effective amount.
  • the present invention provides for the use of the domain antibody construct according to the first aspect of the invention in a diagnostic application for detecting human TNF- ⁇ .
  • the anti-human TNF- ⁇ domain antibody construct according to the invention can be used to detect human TNF- ⁇ for example in a biological sample, such as serum or plasma using a conventional immunoassay, such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry.
  • a biological sample such as serum or plasma
  • a conventional immunoassay such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry.
  • ELISA enzyme linked immunosorbent assay
  • RIA radioimmunoassay
  • tissue immunohistochemistry tissue immunohistochemistry.
  • the anti-human TNF- ⁇ domain antibody construct according to the invention can be assayed in biological fluids by a competition immunoassay using recombinant human TNF- ⁇ standards labelled with a detectable substance and an unlabelled anti-human TNF- ⁇ antibody.
  • the anti-human TNF- ⁇ domain antibody construct according to the invention may also be used to detect TNF- ⁇ from species other than humans such as non-human primates including cynomolgus, chimpanzee, marmoset, rhesus and other species such as dog, rat, mouse, rabbit, cat, pig, bovine.
  • the anti-human TNF- ⁇ domain antibody construct according to the invention may also be used in cell culture applications where it is desired to inhibit TNF- ⁇ activity.
  • the invention provides a method for treating a disorder characterised by human TNF- ⁇ activity in a human subject, comprising administering to the subject a pharmaceutical composition according to the second aspect of the invention.
  • a disorder characterised by human TNF- ⁇ activity is intended to include diseases and other disorders in which the presence of TNF- ⁇ in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor which contributes to a worsening of the disorder.
  • the disorder characterised by human TNF- ⁇ activity is selected from the group consisting of inflammation, inflammatory diseases, sepsis, including septic shock, endotoxic shock, gram negative sepsis and toxic shock syndrome; autoimmune disease, including rheumatoid arthritis, juvenile arthritis, rheumatoid spondylitis, ankylosing spondylitis, Sjögren's syndrome, osteoarthritis and gouty arthritis, allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis, psoriasis, pemphigoid and nephrotic syndrome; inflammatory conditions of the eye, including macular degeneration, uveitis, Behçet's disease; infectious disease, including fever and myalgias due to infection and cachexia secondary to infection; graft versus host disease; tumour growth or metastasis, hematologic malignancies; pulmonary disorders including asthma, adult respiratory distress syndrome, shock lung, chronic pulmonary inflammatory disease,
  • the disorder characterised by human TNF- ⁇ activity is age-related macular degeneration.
  • TNF- ⁇ is implicated in stimulating VEGF production and promoting neovascularisation in the eye (Oh-H et al., 1999 Investigative Ophthalmology & Visual Science 40:1891-98), and therefore inhibitors of TNF- ⁇ activity, such as the domain antibody constructs described herein, would be useful for therapy of angiogenesis-related ocular disorders including age-related macular degeneration.
  • Marmoset (genus Callithrix , species unknown) and Owl monkey ( Aotus trivirgatus ) genomic DNA were obtained from the European Collection of Cell Cultures (ECACC), catalogue numbers 85011419 and 90110510 respectively. Marmoset DNA was derived from cell line B95-8 while Owl monkey DNA came from cell line OMK 637-69.
  • V ⁇ leader sequences and recombination signal sequences were derived from Walter and Tomlinson, Antibody Engineering: A Practical Approach (1996).
  • the primers used for amplification of germline V ⁇ DNA were as follows:
  • Primer VK1BL AATCKCAGGTKCCAGATG (SEQ ID No:13) Primer VK1BL35a GTTYRGGTKKGTAACACT (SEQ ID No:14) Primer VK1BL35b ATGMCTTGTWACACTGTG (SEQ ID No:15)
  • PCR (30 cycles) was performed using Taq polymerase with either primer pair VK1BLxVK1BL35a or VK1BLxVK1BL35b. There was overlap between the sequences cloned and the two primer sets used.
  • Genomic PCR products were cloned into Invitrogen's TOPO TA cloning kit (Cat No K4500-01) and sequenced with M13 Forward and pUC Reverse primers. Sequence was confirmed in forward and reverse directions. In order to further confirm key sequences were not subject to PCR errors, the PCR and cloning process was repeated twice for marmoset sequences. Nucleotide (SEQ ID Nos:16-26 and SEQ ID Nos:38-43) and amino acid (SEQ ID Nos:27-37 and SEQ ID Nos:44-49) are given in FIG. 3 (A-G). Marmoset sequences 1, 2 and 3 were confirmed. Sequences 4, 5, 6, 7 and 8 were seen only in the initial PCR. Sequences 9, 10 and 11 were seen only in the repeat (ie second) PCR and cloning.
  • AATKLQS (SEQ ID No:1) from Owl monkey sequence 1 (SEQ ID No:44), EASSLQS (SEQ ID No:2) from Owl monkey sequence 2 (SEQ ID No:45), EASKLQS (SEQ ID No:3) from Marmoset sequence 1 (SEQ ID No:27), and SASNLET (SEQ ID No:4) from Marmoset sequence 2 (SEQ ID No:28), were chosen from the amino acid sequences shown in FIG. 3 (A-G).
  • Owl Monkey sequence 5 YASSLQS (SEQ ID No:56) was found to be identical to GI6176295 an Aotus nancymaae (Ma's night monkey) cDNA sequence, all other sequences were unique.
  • acceptor variable region (anti-TNF domain antibody) sequence in the expression vector was digested (25 ⁇ g) sequentially with KpnI and SanDI which excises the majority of FR2 as well as CDR2 as indicated on the restriction digest map, FIG. 4 .
  • the vector was then gel purified to remove the excised wild-type FR2 and CDR2 sequence.
  • Oligo annealing was performed by incubating oligo pairs (500 pmol, based on sequences shown in FIG. 3 (A-G)) at 95° C. for 5 minutes followed by 65° C. for 5 minutes and then allowed to reach room temperature slowly on a hot block. Overlaps were then filled in during a Klenow reaction in the presence of dNTPs. Molecular cloning of the synthetic double-stranded DNA (derived by oligo annealing and end filling) into the acceptor variable region sequence was achieved using standard methods.
  • the marmoset CDR-grafted dAb Compound 145 (SEQ ID No:7) was affinity matured by constructing 14 separate libraries, each a diversification of the sequence of SEQ ID No:7 at a single amino acid residue. The selected residues are shown bolded below.
  • CHOK1SV cells (Lonza Biologics, UK), a suspension variant of CHOK1, were maintained in logarithmic growth phase in CD CHO media supplemented with 6 mM L-glutamine (Invitrogen Cat Nos. 10743-029 and 25030-081). Cultures were incubated at 36.5° C., 10% CO 2 and shaking at 140 rpm. 24 hours before transfection cell number and viability was assessed by trypan blue exclusion (Sigma Cat No. T8154) on a haemocytometer.
  • Each sequence was flanked at the 5′ end with a Hind III site, a Kozak sequence (GCCACC; SEQ ID No:57) and a human IgG kappa leader sequence (amino acid sequence MSVPTQVLGLLLLWLTDARC; SEQ ID No:58).
  • GCCACC Kozak sequence
  • MSVPTQVLGLLLLWLTDARC human IgG kappa leader sequence
  • At the 3′ end two stop codons and an EcoR I site were added to each sequence.
  • Following synthesis genes were provided cloned into a pCRScript vector (Stratagene) and were released by Hind III/EcoR I digestion in the appropriate restriction enzyme buffer (Roche Diagnostics Cat Nos. 10656313001, 10703737001 and 11417967001 respectively).
  • the GS expression vector pEE12.4 (Lonza Biologics, UK) was similarly digested and dephosphorylated using calf intestinal alkaline phosphatase Roche Diagnostics Cat No. 10713023001). Each gene was ligated into the prepared pEE12.4 backbone using the LigaFast Rapid DNA Ligation System from Promega (Cat No. M8221). Ligations were then transformed into One Shot Top 10 chemically competent cells (Invtrogen Cat No. C4040-03) and positive colonies identified by standard techniques. Large quantities of the resulting vectors (pEE12.4-PNO621 and pEE12.4-PNO521-S114C) were prepared by midiprep of overnight cultures using QIAfilter midiprep columns (QIAgen Cat No.
  • Vectors were prepared for transfection by precipitating 20 ⁇ g in 100% ethanol with 1/10 volume of 3 M sodium acetate (pH 5.2) (Sigma Cat Nos. E7023 and 52889 respectively). Following a wash in 70% ethanol, vectors were resuspended in 40 ⁇ l of T.E. pH 8.0 (Sigma Cat No. T9285) at a working concentration of 0.5 ⁇ g/ ⁇ l.
  • Microtitre plates (e.g. Sarstedt 82.9923-148) were coated with a 1 ⁇ g/mL solution of human recombinant TNF- ⁇ (Peprotech Cat # 300-01A) in carbonate/bicarbonate coating buffer pH 9.6, 100 ⁇ L/well. After overnight incubation at 4° C., plates were washed 3 times with PBS (0.01 M, pH 7.2) with 0.05% Tween 20, and 3 times with PBS. 200 ⁇ L blocking buffer (PBS with 1% BSA ⁇ bovine serum albumin, Sigma Cat #A-9647 ⁇ ) was added per well and incubated at 25° C. for 1 hour.
  • PBS 1% BSA ⁇ bovine serum albumin
  • ABTS substrate (2,2′-Azino-bis(3-Ethylbenz-Thiazoline-6-Sulfonic acid) diammonium salt, Sigma Cat # A-1888, 0.5 mg/mL in citrate buffer pH 4.4, with 0.03% H 2 O 2 ) were added per well.
  • Substrate was developed for 30 minutes at room temperature and absorbance read at 405 nm (reference 620 nm). Sample concentrations were determined relative to the standard curve and were expressed relative to the mean concentration of Compound 112 expressed.
  • truncated C H 1 in the domain antibody construct results in a junction between the variable domain and hinge with higher homology to a conventional IgG i C H 1-hinge junction (91.7%) than a junction lacking the truncated C H 1 (83.3%; calculated using Align X on Vector NTI (Invitrogen) with a gap opening penalty of 1).
  • Enhanced homology is likely to translate to increased resemblance to conventional immunoglobulin peptide sequences to which human patients should be immunologically tolerant, thereby reducing immunogenic potential.
  • TKVEIKR V EPKS (SEQ ID NO: 65) IgG 1 C H 1-hinge junction (NCBI accession AAG00909): TKVDKRV EPKS (SEQ ID NO: 66)
  • TKVEIKREPKS (SEQ ID NO: 67)
  • C H 1 sequence is bolded as indicated.
  • C H 1 domain (SEQ ID No:60) obtained from NCBI protein database (http://www.ncbi.nlm.nih.gov) AAG00909:
  • the ability of the domain antibody construct Compound 170 (SEQ ID No:11) to neutralize TNF- ⁇ -mediated cytotoxicity was assessed using a murine L929 cell viability assay.
  • Serial dilutions of Compound 170 in RPMI medium with 10% foetal bovine serum (RPMI-FBS) were prepared in 50 ⁇ L volumes in flat bottomed 96 well plates.
  • RPMI-FBS foetal bovine serum
  • Controls included wells with no TNF (for determination of 100% viability), no cells (0% viability) and a TNF- ⁇ standard curve ranging from 2 pg/mL to 4200 pg/mL.
  • Culture plates were incubated in a 5% CO 2 atmosphere at 37° C. for 20 hours, then for a further 3 hours after the addition of 25 ⁇ L 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)/phenazine ethosulfate (PES) (Promega CellTiter 96 AQ ueous One, Madison USA).
  • the ability of the domain antibody construct Compound 170 (SEQ ID No:11) to inhibit binding of TNF- ⁇ to human p55 and p75 TNF receptors was evaluated by receptor binding assays.
  • Human p55 (RnD systems, Cat No: 372-RI) or p75 (RnD systems, Cat No: 762-R2) was coated onto Maxisorb plates (Nunc) at 0.1 ⁇ g/mL in carbonate coating buffer pH 9.2 by overnight incubation at 4° C.
  • Serial half-log dilutions of Compound 170 ranging from 100 ⁇ g/mL down to 3.15 ng/mL (and a no Compound 170 ‘blank’ control) were prepared in antibody diluent (PBS pH 7.2, 0.05% Tween-20, 1% BSA) and were mixed with an equal volume of 60 ng/mL human TNF- ⁇ in antibody diluent.
  • a blank containing no PN0621 and no TNF- ⁇ was also prepared to measure background binding. All mixtures were allowed to incubate for exactly 1 hour at room temperature with gentle agitation. During this incubation the coated plates were washed 3 times with PBS, 0.05% Tween-20 and then 3 times with PBS.
  • the plates were then blocked with 200 ⁇ l/well of PBS, 1% BSA for 45 minutes at room temperature. Following washing of the plate, 100 ⁇ l of the Compound 170/TNF- ⁇ mixtures were added to triplicate wells for each concentration of Compound 170 tested along with addition of all the controls. The plate was then incubated at room temperature for 1 hour. Following washing of the plate, a biotinylated anti-human TNF- ⁇ antibody (RnD Systems, Cat No: BAF210) was added at 0.6 ⁇ g/mL in antibody diluent to each well and incubated for 1 hour at room temperature.
  • TNF- ⁇ a similar cell line based on another murine myeloma (SP2/0) has been described (Scallon et al., (1995) Cytokine 7 251-259).
  • Flow cytometry analysis was performed on 5 ⁇ 10 5 viable 27D4 cells per sample with all steps performed at 4° C. or on ice.
  • Cell pellets were resuspended with test (Compound 170; SEQ ID No:11) or irrelevant-specificity isotype-matched control (Sigma, Cat No: I5154) at 100 ⁇ g/ml in PBS containing 2% FBS, and incubated on ice for 1 hour.
  • Two cell wash cycles were performed, each comprising, centrifugation for 10 minutes at 1000 ⁇ g and resuspension of the cell pellet in PBS/2% FBS.
  • the cell pellet was resuspended in 100 ⁇ l secondary antibody conjugate (Anti-human Fc FITC conjugate, Sigma, Cat No: F9512) and incubated for 30 mins. The samples were then washed twice as described above and cell pellets resuspended in 500 ⁇ l PBS/2% FBS with 5 ⁇ g/mL propidium iodide (Sigma, Cat no: P4864). Fluorescent staining of cells was analysed on a Beckman Coulter Cell Lab Quanta flow cytometer and data was processed using WinMDI.
  • Stable cell lines of CHOK1SV expressing Compound 170 were created using the expression vector described in the Materials and Methods. Briefly 1 ⁇ 10 7 cells in logarithmic growth phase were electroporated in glutamine-free CDCHO protein-free media in the presence of 40 ⁇ g of linearised plasmid DNA. 24 hours post-transfection a selective pressure of 50 ⁇ M methionine sulphoximine (Sigma) was applied and resistant cells were allowed to form colonies in 96 well plates. When approaching confluence, single colonies were transferred to 24 well plates, T25 and then T75 flasks.
  • productivity assessments were performed in parallel to the progress of the cell lines to the next stage. Thus at the 24 well plate and E125 Erlenmeyer flask stages productivity assessments were performed. In each case cells were allowed to grow for 14 days and supernatants evaluated by the TNF ELISA method described in Example 1 for levels of Compound 170. Cell lines were ranked on the productivity and the highest 10 were selected for evaluation in a proprietary fed-batch productivity assessment at Lonza Biologics. Productivities obtained were between 700 mg/L and 3371 mg/L. A lead cell line with a productivity of 2724 mg/L was selected for evaluation in 10 L laboratory scale fermenters.
  • ESI-MS electrospray ionisation mass spectrometry
  • Compound 170 (SEQ ID No:11) was administered subcutaneously to cynomolgus monkeys at doses of 0.5, 5 and 50 mg/kg, and blood samples were taken at 0.5, 1, 2, 6 and 24 hours then at 1 day, 2, 4, 7, 10 and 14 days. Analysis of these samples for quantitation of Compound 170 levels was performed using the anti-TNF ELISA method described in Example 1. Elimination half-life was determined by analysis of the levels of Compound 170 in these samples. At 0.5 mg/Kg an elimination half-life of 110.5 ⁇ 13.9 hours was calculated. At 5 mg/Kg and 50 mg/Kg elimination half-lives of 110.9 ⁇ 10.4 and 103.5 ⁇ 11.5 hours were calculated.
  • Compound 170 (SEQ ID No:11) manufactured to GMP standards was evaluated in animal safety and toxicology studies.
  • Compound 170 (SEQ ID No:11) in preceding examples was produced in mammalian expression systems. Functional Compound 170 was also produced using a bacterial expression system.
  • the amino acid sequence for Compound 170 minus the signal sequence was back-translated and optimized by GeneOptimizerTM for E. coli expression and synthesized de novo at GeneArt GmbH.
  • the synthesized gene was subcloned into the pBAD gIII/His-tagged expression vector (Invitrogen) via NcoI and HindIII restriction sites (Roche) generating a vector ready for bacterial expression.
  • TOP10 cells (Invitrogen) were transformed with the vector by the heat shock method and glycerol stocks of single colonies generated. Induction conditions were 0.002% arabinose (Sigma; final concentration) and 4 hr induction period.
  • Compound 170 protein samples were generated using the osmotic shock method as detailed in the pBAD bacterial expression system manual (Invitrogen). The BCA assay (Pierce) was used to determine the total protein concentration of the samples. Bacterially-expressed Compound 170 was assayed for binding to TNF- ⁇ in an ELISA as described in Example 1.
  • FIG. 9 shows that Compound 170 produced in a bacterial system retained binding to TNF- ⁇ in an ELISA assay.
  • amino acid sequence encoded by SEQ ID No:61 is as follows:
  • the human TNF transgenic mouse line, Tg197 shows deregulated TNF expression and develops chronic inflammatory polyarthritis (Keffer, J. et. al. (1991) Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO Journal 10:4025-31). Administration of Compound 170 (SEQ ID No:11) prevented the development of arthritis and associated weight loss in these mice ( FIGS. 10A & B).
  • mice Groups of 8 heterozygous Tg197 (each containing 4 males and 4 females) were treated with twice weekly intraperitoneal injections of Compound 170 and irrelevant specificity control human IgG 1 (palivizumab ⁇ Synagis® ⁇ , MedImmune/Abbott) in PBS, both at 10 mg/kg. Treatment commenced when mice were 3 weeks of age. At weekly intervals, mice were weighed and scored (arthritic score) based on macroscopic ankle morphology (swelling, distortion and degree of movement).
  • Compound 112 (SEQ ID No: 59) is a modification of Compound 170 (SEQ ID No:11) which contains a cysteine residue at position 114 instead of a serine residue which is present in this position in Compound 170.
  • the effect of substituting cysteine 114 for serine on protein expression was evaluated by comparison with Compound 170.
  • Multiple cultures of host cells transfected with gene constructs for Compound 112 and 170 were assayed for protein expression by ELISA with solid phase TNF as set out in Materials and Methods. The results are set out in FIG. 11 .

Abstract

The present invention provides a domain antibody construct which binds to human TNF-α, with the construct comprising:
    • (a) a domain antibody (dAb) which binds to human TNF-α;
    • (b) a modified hinge region sequence;
    • (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues,
    • wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 11/670,261, filed Feb. 1, 2007, which claims the benefit of U.S. Provisional Patent Application No. 60/817,507, filed Jun. 28, 2006, which claims the benefit of Australian Patent Application No. 2006900456, filed Feb. 1, 2006, and which are hereby incorporated by reference in their entirety.
  • FIELD OF THE INVENTION
  • The present invention relates to a domain antibody construct useful for human therapy. More particularly, the present invention relates to a domain antibody construct which binds to human TNF-α and its use in the treatment of disorders characterised by TNF-α activity.
  • BACKGROUND OF THE INVENTION
  • Tumor necrosis factor alpha (TNF-α) is a cytokine that has been implicated in mediating shock and the pathophysiology of a variety of human diseases and disorders including sepsis, infections, autoimmune diseases eg. rheumatoid arthritis, Crohn's disease, ulcerative colitis and other bowel conditions, psoriasis, toxic shock, transplant rejection and graft-versus-host disease. TNF-α is produced primarily by activated macrophages and T lymphocytes, but also by neutrophils, endothelial cells, keratinocytes and fibroblasts during acute inflammatory reactions.
  • Because of its role in inflammation, TNF-α has emerged as an important target for inhibition in efforts to reduce the symptoms of inflammatory disorders. Various approaches to inhibition of TNF-α for the clinical treatment of disease have been pursued, including particularly the use of soluble TNF-α receptors and antibodies specific for TNF-α.
  • Domain Antibodies
  • Domain antibodies (dAb) are the smallest functioning binding units of antibodies and correspond to the variable regions of either the heavy (VH) or light (VL) chains of antibodies. Domain antibodies have a molecular weight of approximately 13 kDa, or less than one tenth the size of a full antibody.
  • In contrast to conventional antibodies, domain antibodies are well expressed in bacterial, yeast and mammalian systems. Their small size allows for higher molar quantities per gram of product, thus providing a significant increase in potency per milligram dose. In addition, dAbs can be used as building blocks to create therapeutic products such as multiple targeting dAb-containing molecules in which two or more dAbs bind to two or more distinct molecular targets, or dAbs may be incorporated into structures designed for pulmonary or oral administration.
  • The present inventors have now devised a novel domain antibody construct comprising an immunoglobulin variable domain linked to a constant region including a truncated C H1 domain. It is postulated that the inclusion of a constant region will assist in prolonging the in vivo half-life of the dAb which is typically of a short duration.
  • New World Primate Immunoglobulin
  • Evolutionarily distant primates, such as New World primates are sufficiently similar to human to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primate-derived antibodies are introduced into a human. New World primates (infraorder-Platyrrhini) comprise at least 53 species commonly divided into two families, the Callithricidae and Cebidae. The Callithricidae consist of marmosets and tamarins. The Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, night or owl monkey and the howler monkey.
  • Previous studies have characterised the expressed immunoglobulin heavy chain repertoire of the Callithrix jacchus marmoset (von Budingen H—C et al., Characterization of the expressed immunoglobulin IGHV repertoire in the New World marmoset Callithrix jacchus. Immunogenetics; 53:557-563 (2001)). Six IGHV subgroups were identified which showed a high degree of sequence similarity to their human IGHV counterparts. The framework regions were more conserved when compared to the complementarity determining regions (CDRs), with the greatest degree of variability located in CDR3. The degree of similarity between C. jacchus and human IGHV sequences was less than between Old World monkeys and humans.
  • SUMMARY OF THE INVENTION
  • In a first aspect, the present invention provides a domain antibody construct which binds to human TNF-α, the construct comprising:
  • (a) a domain antibody (dAb) which binds to human TNF-α
  • (b) a modified hinge region sequence;
  • (c) a human or primate heavy chain constant region sequence having a truncated C H1 domain of not more than 20 residues, more preferably not more than 10 residues, still more preferably not more than 5 residues and even more preferably a single residue;
  • wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of the cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
  • In a second aspect the present invention provides a nucleic acid sequence encoding the domain antibody construct of the first aspect of the invention.
  • In a third aspect the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF-α, wherein the nucleic acid molecule comprises a nucleic acid sequence at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:50 or SEQ ID No:51 and most preferably, the sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • In a fourth aspect the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF-α, wherein the nucleic acid molecule comprises a nucleic acid sequence which hybridises under conditions of high stringency to the nucleotide sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • In a fifth aspect, the invention provides a pharmaceutical composition comprising an effective amount of the domain antibody construct according to the first aspect, together with a pharmaceutically acceptable carrier or diluent.
  • In a sixth aspect, the present invention provides for the use of the domain antibody construct according to the first aspect of the invention in a diagnostic application for detecting human TNF-α.
  • In a seventh aspect, the invention provides a method for treating a disorder characterised by human TNF-α activity in a human subject, comprising administering to the subject a pharmaceutical composition according to the fifth aspect of the invention.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows the amino acid (SEQ ID No:5) and nucleotide sequence (SEQ ID No:6) of the acceptor dAb.
  • FIG. 2 shows the structure of the preferred embodiment of the domain antibody construct according to the present invention as (A) a monomer and (B) a dimer.
  • FIG. 3(A-G) shows the nucleotide and amino acid sequences of eleven (11) marmoset and six (6) Owl monkey Vκ gene segments.
  • FIG. 4 shows the acceptor dAb amino acid (SEQ ID NO:5) and nucleotide sequence (both strands) (SEQ ID NO:6 AND SEQ ID NO:68). The restriction digest sites for Kpn I and San DI which excises region including the CDR2 is indicated in the figure. CDR2 residues removed are indicated in underlined.
  • FIG. 5 shows the ability of Compound 170 (SEQ ID No:11) to neutralise TNF-α mediated cytotoxicity in a murine L929 cell viability assay.
  • FIG. 6 shows that Compound 170 (SEQ ID No:11) prevents the interaction of TNF-α with the human p55 or p75 TNF receptors.
  • FIG. 7 shows Compound 170 (SEQ ID No:11) staining of transmembrane TNF-α-expressing NS0 27D4 cells (solid black line) shows higher fluorescence intensity than irrelevant specificity isotype-matched control (grey fill).
  • FIG. 8 shows Compound 170 (SEQ ID No:11) produced in a bacterial expression system retained binding to TNF-α in an ELISA.
  • FIG. 9 shows the efficacy of Compound 170 (SEQ ID No:11) in a TNF-mediated murine arthritis model relative to specificity control human IgG1. At weekly intervals mice were scored (arthritic score), (A), and weighed, (B).
  • FIG. 10 shows the effect on protein expression of Compound 112 (SEQ ID No:59) and Compound 170 (SEQ ID No:11).
  • FIG. 11 shows non-reducing SDS PAGE analysis of Protein A purified Compound 170 (SEQ ID No:11) from 4×10 L fermentations of the lead cell line; lane 1=inter-assay control; lane 2=molecular weight markers; lane 3=blank; lane 4=Protein A purified Compound 170 (SEQ ID No:11) in 10 L fermentation ID (run 1); lane 5=Protein A purified Compound 170 in 10 L fermentation ID (run 2); lane 6=Protein A purified Compound 170 in 10 L fermentation ID (run 3); lane 7=Protein A purified Compound 170 in 10 L fermentation ID (run 4).
  • FIG. 12 shows reducing SDS PAGE analysis of Protein A purified Compound 170 (SEQ ID No:11) from 4×10 L fermentations of the lead cell line; lane 1=inter-assay control; lane 2=molecular weight markers; lane 3=blank; lane 4=Protein A purified Compound 170 (SEQ ID No:11) in 10 L fermentation ID (run 1); lane 5=Protein A purified Compound 170 in 10 L fermentation ID (run 2); lane 6=Protein A purified Compound 170 in 10 L fermentation ID (run 3); lane 7=Protein A purified Compound 170 in 10 L fermentation ID (run 4).
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present inventors have generated a domain antibody construct which binds to human TNF-α and which is postulated to exhibit low immunogenicity when administered to humans. The domain antibody construct comprises a portion corresponding to a variable domain of an immunoglobulin heavy or light chain (ie. a domain antibody (dAb)), a hinge region and a portion corresponding to a constant region of an antibody heavy chain but wherein the constant region has a truncated C H1 domain.
  • The inclusion of the constant region portion is postulated to increase the in vivo half life of the dAb as well as providing effector functions which are believed to be a component of the anti-inflammatory mechanism of anti-TNF antibodies.
  • In a first aspect, the present invention provides a domain antibody construct which binds to human TNF-α, the construct comprising:
  • (a) a domain antibody (dAb) which binds to human TNF-α
  • (b) a modified hinge region sequence;
  • (c) a human or primate heavy chain constant region sequence having a truncated C H1 domain of not more than 20 residues, more preferably not more than 10 residues, still more preferably not more than 5 residues and even more preferably a single residue;
  • wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of the cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
  • In a preferred embodiment the sequence of the C H1 domain and the hinge region is XEPKSZDKTHTCPPCPA (SEQ ID NO:64) wherein X is valine, leucine or isoleucine and Z is absent or an amino acid other than cysteine. It is preferred that X at position one is valine and Z is serine.
  • In a preferred embodiment of the present invention the dAb comprises an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate wherein the CDR is selected from the group consisting of AATKLQS (SEQ ID No:1), EASSLQS (SEQ ID No:2), EASKLQS (SEQ ID No:3), and SASNLET (SEQ ID No:4)
  • In another preferred embodiment the CDR is CDR2.
  • In a preferred embodiment the dAb has a sequence selected from the group consisting of:
  • (Compound 145; SEQ ID No: 7)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
    (Compound 123; SEQ ID No: 8)
    DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI
    YSASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPF
    TFGQGTKVEIKR
    (Compound 100; SEQ ID No: 9)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
    (Compound 196; SEQ ID No: 10)
    DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI
    YSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPF
    TFGQGTKVEIKR
    (Compound 134; SEQ ID No: 52)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKPPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
    (Compound 137; SEQ ID No: 53)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGRGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
    (Compound 121; SEQ ID No: 54)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLVPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR;
    and

    a sequence at least 95%, more preferably at least 96%, 97%, 98% or 99% identical to one of these sequences.
  • In a further preferred embodiment the constant region comprises C H2 and C H3 domains which together have the following sequence:
  • (SEQ ID NO: 63)
    PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
    DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
    LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
    SCSVMHEALHNHYTQKSLSLSPGK;

    or an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical thereto.
  • In another preferred embodiment the domain antibody construct comprises an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:11, and most preferably the sequence set forth in SEQ ID No:11.
  • The term “binds to” as used herein, is intended to refer to the binding of an antigen by an immunoglobulin variable region with a dissociation constant (Kd) of 1 μM or lower as measured by surface plasmon resonance analysis using, for example a BIAcore™ surface plasmon resonance system and BIAcore™ kinetic evaluation software (eg. version 2.1). The affinity or dissociation constant (Kd) for a specific binding interaction is preferably about 500 nM or lower, more preferably about 300 nM or lower and preferably at least 300 nM to 50 pM, 200 nM to 50 pM, and more preferably at least 100 nM to 50 pM, 75 nM to 50 pM, 10 nM to 50 pM. The term “dAb” as used herein refers to an antibody single variable domain (VH or VL) polypeptide that specifically binds antigen.
  • In a further preferred embodiment of the present invention the domain antibody construct forms a homo- or heterodimer with another domain antibody construct according to the present invention. Dimerisation can increase the strength of antigen binding, wherein the strength of binding is related to the sum of the binding affinities of the multiple binding sites. To facilitate dimer formation, the hinge region of the domain antibody construct comprises at least one, and preferably two, cysteine residues.
  • In a particularly preferred embodiment of the present invention, the domain antibody construct forms a homodimer with an identical domain antibody construct.
  • Accordingly in another aspect the present invention provides a dimeric domain antibody construct which binds to human TNF-α wherein the dimer consists of two domain antibody constructs according to the present invention.
  • It is preferred that the dimeric domain antibody construct is a homodimer and it is particularly preferred that the domain antibody constructs making up the homodimer comprise an amino acid sequence which is at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:11, and most preferably the sequence set forth in SEQ ID No:11.
  • In a second aspect the present invention provides a nucleic acid sequence encoding the domain antibody construct of the first aspect of the invention.
  • In a third aspect the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF-α, wherein the nucleic acid molecule comprises a nucleic acid sequence at least 60%, preferably at least 80% identical, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID No:50 or SEQ ID No:51 and most preferably, the sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • In a fourth aspect the present invention provides an isolated nucleic acid molecule comprising a sequence encoding a domain antibody construct which binds human TNF-α, wherein the nucleic acid molecule comprises a nucleic acid sequence which hybridises under conditions of high stringency to the nucleotide sequence set forth in SEQ ID No:50 or SEQ ID No:51.
  • In determining whether or not two polypeptide sequences fall within percentage identity limits, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison or multiple alignment of sequences. In such comparisons or alignments, differences will arise in the positioning of non-identical residues, depending upon the algorithm used to perform the alignment. In the present context, reference to a ‘percentage identity’ or ‘similarity’ between two or more amino acid sequences shall be taken to refer to the number of identical and similar residues respectively, between said sequences as determined using any standard algorithm known to those skilled in the art. For example, amino acid sequence identities or similarities may be calculated using the GAP programme and/or aligned using the PILEUP programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America (Devereaux et al, 1984). The GAP programme utilizes the algorithm of Needleman and Wunsch (1970) to maximise the number of identical/similar residues and to minimise the number and length of sequence gaps in the alignment. Alternatively or in addition, wherein more than two amino acid sequences are being compared, the Clustal W programme of Thompson et al, (1994) is used.
  • In determining whether or not two nucleotide sequences fall within these percentage limits, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison or multiple alignment of sequences. In such comparisons or alignments, differences may arise in the positioning of non-identical residues, depending upon the algorithm used to perform the alignment. In the present context, reference to a percentage identity between two or more nucleotide sequences shall be taken to refer to the number of identical residues between said sequences as determined using any standard algorithm known to those skilled in the art. For example, nucleotide sequences may be aligned and their identity calculated using the BESTFIT programme or other appropriate programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America (Devereaux et al, Nucl. Acids Res., 12:387-395, 1984).
  • High stringency preferably involves hybridisation under conditions of 65° C. and 0.1×SSC {1×SSC=0.15 M NaCl, 0.015 M Na3 Citrate pH 7.0}.
  • In one embodiment, the invention is further based on a method for amplification of New World primate immunoglobulin variable region genes, for example by polymerase chain reaction (PCR) from nucleic acid extracted from New World primate lymphocytes using primers specific for heavy and light chain variable region gene families. For example, information regarding the boundaries of the variable domains of heavy and light chain genes (VH and VL respectively) can be used to design PCR primers that amplify the variable domain from a cloned heavy or light chain coding sequence encoding an antibody known to bind a given antigen. The amplified variable region is then inserted either alone or as a fusion with another polypeptide sequence for the human or primate constant region sequence of the invention into a suitable expression vector for production of the domain antibody construct of the invention. Suitable expression vectors will be familiar to those skilled in the art.
  • The repertoire of VH, VL and constant region domains can be a naturally occurring repertoire of immunoglobulin sequences or a synthetic repertoire. A naturally occurring repertoire is one prepared, for example, from immunoglobulin-expressing cells harvested from one or more primates. Such repertoires can be naïve ie. prepared from newborn immunoglobulin expressing cells, or rearranged ie. prepared from, for example, adult primate B cells. If desired, clones identified from a natural repertoire, or any repertoire that bind the target antigen are then subject to mutagenesis and further screening in order to produce and select variants with improved binding characteristics.
  • Synthetic repertoires of single immunoglobulin variable domains are prepared by artificially introducing diversity into a cloned variable domain.
  • A repertoire of VH and VL domains can be screened for desired binding specificity and functional behaviour by, for example phage display. Methods for the construction of bacteriophage display libraries and lambda phage expression libraries are well known in the art. The phage display technique has been described extensively in the art and examples of methods and compounds for generating and screening such libraries and affinity maturing the products of them can be found in, for example, Barbas et al. (1991) PNAS 88:7978-7982; Clarkson et al. (1991) Nature 352:624-628; Dower et al. PCT. 91/17271, U.S. Pat. No. 5,427,908, U.S. Pat. No. 5,580,717 and EP 527,839; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Garrad et al. (1991) Bio/Technology 9:1373-1377; Garrard et al. PCT WO 92/09690; Gram et al. (1992) PNAS 89:3576-3580; Griffiths et al. (1993) EMBO J. 12:725-734; Griffiths et al. U.S. Pat. No. 5,885,793 and EP 589,877; Hawkins et al. (1992) J Mol Biol 226:889-896; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; Huse et al. (1989) Science 246:1275-1281; Knappik et al. (2000) J Mol Biol 296:57-86; Knappik et al. PCT WO 97/08320; Ladner et al. U.S. Pat. No. 5,223,409, No. 5,403,484, No. 5,571,698, No. 5,837,500 and EP 436,597; McCafferty et al. (1990) Nature 348:552-554; McCafferty et al. PCT. WO 92/01047, U.S. Pat. No. 5,969,108 and EP 589,877; Salfeld et al. PCT WO 97/29131, U.S. Provisional Application No. 60/126,603; and Winter et al. PCT WO 92/20791 and EP 368,684.
  • Recombinant libraries expressing the repertoire of VH and VL domains can be expressed on the surface of microorganisms eg. yeast or bacteria (see PCT publications WO 99/36569 and 98/49286).
  • The domain antibody construct of the invention may be produced by recombinant means, including from eukaryotic expression systems including, for example, yeast, higher plant, insect and mammalian cells, as well as fungi and virally-encoded expression systems, as described herein or as known in the art.
  • The domain antibody constructs of the present invention can be prepared using an S antibody encoding nucleic acid to provide transgenic plants and cultured plant cells (e.g., but not limited to tobacco and maize) that produce such constructs in the plant parts or in cells cultured therefrom. As a non-limiting example, transgenic tobacco leaves expressing recombinant proteins have been successfully used to provide large amounts of recombinant proteins, e.g., using an inducible promoter (see, e.g., Cramer et al., Curr. Top. Microbol. Immunol. 240:95-118 1999) and references cited therein. Also, transgenic maize has been used to express mammalian proteins at commercial production levels, with biological activities equivalent to those produced in other recombinant systems or purified from natural sources (see, e.g., Hood et al., Adv. Exp. Med. Biol. 464:127-147 1999 and references cited therein). Antibodies have also been produced in large amounts from transgenic plant seeds including antibody fragments, such as single chain antibodies (scFv's), including tobacco seeds and potato tubers (see, e.g., Conrad et al., Plant Mol. Biol. 38:101-109 1998 and reference cited therein). Thus, the domain antibody constructs of the present invention can also be produced using transgenic plants, according to known methods (see also, e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99-108 October, 1999: Ma & Hein., Trends Biotechnol. 13:522-7 1995; Ma et al., Plant Physiol. 109:341-6 1995; Whitelam et al., Biochem. Soc. Trans. 22:940-944 1994; and references cited therein; each of the above references is entirely incorporated herein by reference).
  • The domain antibody constructs of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a eukaryotic host, including, for example, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the antibody constructs of the present invention can be glycosylated or can be non-glycosylated, with glycosylated preferred. Such methods are described in many standard laboratory manuals Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, N.Y. 1989, Sections 17.37-17.42; Ausubel et al, eds. Current Protocols in Molecular Biology 1987-1993, Chapters 10, 12, 13, 16, 18 and 20, Colligan et al., Current Protocols in Protein Science, John Wiley & Sons, NY, N.Y. 1997-2001, Protein Science, Chapters 12-14, all entirely incorporated herein by reference.
  • In one expression system the recombinant peptide/protein library is displayed on ribosomes (for examples see Roberts, R W and Szostak, J. W. 1997 Proc. Natl. Acad. Sci. USA. 94:12297-123202 and PCT Publication No. WO98/31700). Thus another example involves the generation and in vitro transcription of a DNA library (eg of antibodies or derivatives preferably prepared from immunised cells, but not so limited), translation of the library such that the protein and “immunised” mRNAs stay on the ribosome, affinity selection (eg by binding to RSP), mRNA isolation, reverse translation and subsequent amplification (eg by polymerase chain reaction or related technology). Additional rounds of selection and amplification can be coupled as necessary to affinity maturation through introduction of somatic mutation in this system or by other methods of affinity maturation as known in the state of the art.
  • Another example sees the application of emulsion compartmentalisation technology to the generation of the domain antibodies of the invention. In emulsion compartmentalisation, in vitro and optical sorting methods are combined with co-compartmentalisation of translated protein and its nucleotide coding sequence in aqueous phase within an oil droplet in an emulsion (see PCT publications no's WO 99/026711 and WO 00/40712).
  • The CDR sequences may be obtained from several sources, for example, databases such as The National Centre for Biotechnology Information protein and nucleotide databases www.ncbi.nlm.nih.gov, The Kabat Database of Sequences of Proteins of Immunological Interest www.kabatdatabase.com, or the IMGT database www.imgt.cines.fr. Alternatively, the CDR regions can be predicted from the VH and VL domain repertoire (see for example Kabat E A and Wu T T Attempts to locate complementarity determining residues in the variable positions of light and heavy chains. Ann. NY Acad. Sci. 190:382-393 (1971)). The CDR sequence may be a genomic DNA or a cDNA.
  • There are a number of ways in which a replacement CDR may be grafted into a variable region sequence and such methods will be familiar to those skilled in the art. The preferred method of the present invention involves replacement of the CDR2 in the variable region (or dAb) via primer directed mutagenesis. This method consists of annealing a synthetic oligonucleotide encoding a desired mutation(s) to a target region where it serves as a primer for initiation of DNA synthesis in vitro, extending the oligonucleotide by a DNA polymerase to generate a double-stranded DNA that carries the desired mutation, and ligating and cloning the sequence into an appropriate expression vector.
  • In a preferred embodiment of the present invention, the New World primate CDR sequence is grafted into a variable region sequence which is of low immunogenicity in humans.
  • By reference to the term “low immunogenicity” it is meant that the domain antibody construct or antigen-binding portion thereof, does not raise an antibody response in a human of sufficient magnitude to reduce the effectiveness of continued administration of the domain antibody construct for a sufficient time to achieve therapeutic efficacy.
  • Preferably, the variable region sequence into which the New World primate CDR is grafted is the “dAb acceptor sequence” (designated Compound 128), in FIG. 1. The dAb acceptor sequence consists of the amino acid sequence set forth in SEQ ID No:5:
  • (SEQ ID No: 5)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASELQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR.
  • This sequence is encoded by the nucleotide sequence set forth in SEQ ID No:6:
  • (SEQ ID No: 6)
    GAC ATC CAG ATG ACC CAG TCT CCA TCC TCT CTG TCT
    GCA TCT GTA GGA GAC CGT GTC ACC ATC ACT TGC CGG
    GCA AGT CAG AGC ATT GAT AGT TAT TTA CAT TGG TAC
    CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG ATC
    TAT AGT GCA TCC GAG TTG CAA AGT GGG GTC CCA TCA
    CGT TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC ACT
    CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT GCT
    ACG TAC TAC TGT CAA CAG GTT GTG TGG CGT CCT TTT
    ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA CGG
  • In one preferred embodiment of the present invention, a marmoset New World primate CDR sequence SASNLET (SEQ ID No:4) is grafted into the variable region dAb acceptor sequence so as to replace the CDR2 sequence (SASELQS; SEQ ID No:55) of the dAb acceptor sequence to produce the following dAb (designated Compound 145):
  • Compound 145
    (SEQ ID No: 7)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
  • Thus, in one preferred embodiment, the dAb of the domain antibody construct which binds to human TNF-α, comprises the amino acid sequence set forth in SEQ ID No:7.
  • It is within the scope of the present invention, that the variable region sequence (dAb) of the domain antibody construct may be further subject to affinity maturation in order to improve its antigen binding characteristics. This may necessitate the modification of certain amino acid residues within CDR1, CDR3 or framework of the domain antibody construct.
  • For example, SEQ ID No:7 was affinity matured as set out in the Materials and Methods and tested for TNF-α-binding. In a further preferred embodiment, the variable region (dAb) of the domain antibody construct which binds to human TNF-α comprises the amino acid sequence of SEQ ID No:8 or SEQ ID No:9. These have been designated Compound 123 and Compound 100 respectively, and their sequences are shown below:
  • Compound 123
    (SEQ ID No: 8)
    DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI
    YSASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPF
    TFGQGTKVEIKR
    Compound 100
    (SEQ ID No: 9)
    DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
  • In a particularly preferred embodiment, the variable region (dAb) of the domain antibody construct which binds to human TNF-α comprises the amino acid sequence of SEQ ID No:10. This has been designated Compound 196 and the sequence is provided below:
  • Compound 196
    (SEQ ID No: 10)
    DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI
    YSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPF
    TFGQGTKVEIKR
  • It will be appreciated by persons skilled in the art that the constant region sequence of the domain antibody construct may be derived from human or primate sequences. The primate sequence may be New World primate or an Old World primate sequence. Suitable Old World primates include chimpanzee, or other hominid ape eg. gorilla or orangutan, which because of their close phylogenetic proximity to humans, share a high degree of homology with the human constant region sequence. Preferably, the constant region is derived from a human antibody sequence. Examples of such sequences can be found in The National Centre for Biotechnology Information protein and nucleotide databases www.ncbi.nlm.nih.gov, and The Kabat Database of Sequences of Proteins of Immunological Interest www.kabatdatabase.com, or the IMGT database www.imgt.cines.fr.
  • In designing the domain antibody construct of the present invention, the inventors have truncated the C H1 domain of the constant (Fc) region. A minimal number of C H1 domain residues have been retained in order to provide flexibility in the domain antibody construct around the hinge region. Preferably, at least 20 C-terminal amino acid residues of the C H1 domain are retained, more preferably at least 10 amino acids, still more preferably at least 5 amino acids, even more preferably a single amino acid residue.
  • Thus, in a preferred embodiment, the domain antibody construct has a format comprising dAb-C terminal C H1 domain residue-hinge region-C H2 domain-C H3 domain as illustrated schematically in FIG. 2.
  • In a particularly preferred embodiment, the domain antibody construct has the amino acid sequence set forth in SEQ ID No:11. This has been designated Compound 170.
  • Compound 170
    (SEQ ID No: 11)
    DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI
    YSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPF
    TFGQGTKVEIKRVEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
    LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
    TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
    QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
    PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
    LSPGK
  • The hinge region of the naturally occurring immunoglobulin contains a cysteine (C) side chain which facilitates the formation of a disulfide bond between the C H1 domain of the heavy chain and the constant domain of the light chain. Because the construct comprises only a single variable domain and thus leaves a potentially reactive unpaired cysteine residue, the cysteine residue has been substituted with an amino acid residue which prevents disulfide bond formation. The potential consequences of having an unpaired cysteine may include reduced protein expression due to aggregation and misfolding of the construct.
  • It is to be understood that any hinge region sequence derived from any of the antibody classes would be appropriate for use in the present invention. It is preferred however, that the hinge region is derived from the antibody subclass IgGi. Preferably, the hinge region is based on the naturally occurring sequence of the hinge region of IgGi and comprises the sequence EPKSSDKTHTCPPCPA (SEQ ID No:12). In this sequence, the Cys which normally occurs at position 5 is replaced by the underlined bolded Ser residue.
  • Preferably, the C-terminal amino acid residue of the C H1 domain is derived from IgG1. More preferably, the C H1 residue is a valine (V) residue or a conservative amino acid substitution such as leucine (L) or isoleucine (I). This residue is located immediately proximal to the hinge region and assists in increasing the flexibility of the construct around the hinge region.
  • Sequences of the C H2 and C H3 domains are preferably derived from Swissprot database accession number P01857:
  • (SEQ ID No: 63)
    PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
    DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
    LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
    SCSVMHEALHNHYTQKSLSLSPGK.
  • The domain antibody construct may be derivatised or linked to another functional molecule. For example, the domain antibody construct can be functionally linked by chemical coupling, genetic fusion, noncovalent association or otherwise, to one or more other molecular entities, such as another antibody, a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody-binding portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • Useful detectable agents with which the domain antibody construct may be derivatised include fluorescent compounds. Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin and the like. The domain antibody construct may also be derivatised with detectable enzymes such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When the domain antibody construct is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product. The domain antibody construct may also be derivatised with biotin, and detected through indirect measurement of avidin or streptavidin binding.
  • The domain antibody construct according to the invention may be linked to one or more molecules which provide increased half-life and resistance to degradation without loss in activity (eg binding affinity) in vivo. These molecules may be linked to the domain antibody construct via a linker so that they do not interfere/sterically hinder the antigen binding site. These adduct molecules include for example dAbs directed to an endogenous molecule as described in US patent application 20050271663. Typically, such adduct molecules are polypeptides or fragments of polypeptides which occur naturally in vivo and which resist degradation or removal by endogenous mechanisms. Molecules which increase half life may be selected from the following:
  • (a) proteins from the extracellular matrix, eg. collagen, laminin, integrin and fibronectin;
    (b) proteins found in blood, eg. fibrin α-2 macroglobulin, serum albumin, fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, protein, ubiquitin, uteroglobulin, β-2 microglobulin, plasminogen, lysozyme, cystatin C, alpha-1-antitrypsin and pancreatic kypsin inhibitor;
    (c) immune serum proteins, eg. IgE, IgG, IgM;
    (d) transport proteins, eg. retinol binding protein, α-1 microglobulin;
    (e) defensins, eg. beta-defensin 1, neutrophil defensins 1, 2 and 3;
    (f) proteins found at the blood brain barrier or in neural tissues, eg. melanocortin receptor, myelin, ascorbate transporter;
    (g) transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (see U.S. Pat. No. 5,977,307); brain capillary endothelial cell receptor, transferrin, transferrin receptor, insulin, insulin-like growth factor 1 (IGF 1) receptor, insulin-like growth factor 2 (IGF 2) receptor, insulin receptor;
    (h) proteins localised to the kidney, eg. polycystin, type IV collagen, organic anion transporter K1, Heymann's antigen;
    (i) proteins localised to the liver, eg. alcohol dehydrogenase, G250;
    (j) blood coagulation factor X;
    (k) α-1 antitrypsin;
  • (l) HNF 1α;
  • (m) proteins localised to the lung, eg. secretory component (binds IgA);
    (n) proteins localised to the heart, eg. HSP 27;
    (o) proteins localised to the skin, eg, keratin;
    (p) bone specific proteins, such as bone morphogenic proteins (BMPs) eg. BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-1) and -8 (OP-2);
    (q) tumour specific proteins, eg. human trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins eg cathepsin B (found in liver and spleen);
    (r) disease-specific proteins, eg. antigens expressed only on activated T-cells: including LAG-3 (lymphocyte activation gene); osteoprotegerin ligand (OPGL) see Kong Y Y et al Nature (1999) 402, 304-309; OX40 (a member of the TNF receptor family, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human T cell leukaemia virus type-I (HTLV-I)-producing cells—see Pankow R et al J. Immunol. (2000) July 1; 165(1):263-70; metalloproteases (associated with arthritis/cancers), including CG6512 Drosophila, human paraplegin, human FtsH, human AFG3L2, murine ftsH; angiogenic growth factors, including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), transforming growth factor-α (TGF-α), tumor necrosis factor-alpha (TNF-α), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet derived endothelial growth factor (PD-ECGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BB (PDGF), fractalkine;
    (s) stress proteins (heat shock proteins); and
    (t) proteins involved in Fc transport.
  • The present invention also extends to a PEGylated domain antibody construct which provides increased half-life and resistance to degradation without a loss in activity (e.g. binding affinity) relative to non-PEGylated antibody polypeptides.
  • The domain antibody construct can be coupled, using methods known in the art, to polymer molecules (preferably PEG) useful for achieving the increased half-life and degradation resistance properties. Polymer moieties which can be utilised in the invention can be synthetic or naturally occurring and include, but not limited to straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide such as a homo- or heteropolysaccharide. Preferred examples of synthetic polymers which can be used in the invention include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly(vinyl alcohol) and derivatives or substituted forms thereof. Particularly preferred substituted polymers for linkage to the domain antibody construct include substituted PEG, including methoxy(polyethylene glycol). Naturally occurring polymer moieties which can be used in addition to or in place of PEG include lactose, amylose, dextran, or glycogen, as well as derivatives thereof which would be recognised by persons skilled in the art.
  • The polymer (PEG) molecules useful in the invention can be attached to the domain antibody construct using methods which are well known in the art. The first step in the attachment of PEG or other polymer moieties to the domain antibody construct of the invention is the substitution of the hydroxyl end-groups of the PEG polymer by electrophile-containing functional groups. Particularly, PEG polymers are attached to either cysteine or lysine residues present in the domain antibody construct monomers or multimers. The cysteine and lysine residues can be naturally occurring, or can be engineered into the domain antibody construct molecule.
  • Pegylation of the domain antibody constructs of the invention may be accomplished by any number of means (see for example Kozlowski-A & Harris-J M (2001) Journal of Controlled Release 72:217). PEG may be attached to the domain antibody construct either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins is described in Delgado et al., (1992), Crit. Rev. Thera. Drug Carrier Sys. 9:249-304; Francis et al., (1998), Intern. J. Hematol. 68:1-18; U.S. Pat. No. 4,002,531; U.S. Pat. No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.
  • One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monomethoxy polyethylene glycol (MPEG) using tresylchloride. Following reaction of amino acid residues with tresylated MPEG, polyethylene glycol is directly attached to the amine groups. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.
  • Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Pat. No. 5,612,460 discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1′-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number of additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference.
  • In a particularly preferred embodiment of the present invention the domain antibody construct is coupled directly to polyethylene glycol via a lysine residue. In yet another preferred embodiment of the present invention, the domain antibody construct is coupled directly to PEG via a cysteine residue. The unpaired cysteine residue could pre-exist in the sequence, could be added by incorporating a cysteine residue in, for example, the C-terminus of the domain antibody construct. Alternatively, attachment of the PEG to the domain antibody construct could be facilitated via a disulphide bonded cysteine such as that described in US20060210526.
  • Other derivatized forms of polymer molecules include, for example, derivatives which have additional moieties or reactive groups present therein to permit interaction with amino acid residues of the domain antibody constructs described herein. Such derivatives include N-hydroxylsuccinimide (NHS) active esters, succinimidyl propionate polymers, and sulfhydryl-selective reactive agents such as maleimide, vinyl sulfone, and thiol. PEG polymers can be linear molecules, or can be branched wherein multiple PEG moieties are present in a single polymer.
  • The reactive group (e.g., MAL, NHS, SPA, VS, or Thiol) may be attached directly to the PEG polymer or may be attached to PEG via a linker molecule.
  • The size of polymers useful in the invention can be in the range of 500 Da to 60 kDa, for example, between 1000 Da and 60 kDa, 10 kDa and 60 kDa, 20 kDa and 60 kDa, 30 kDa and 60 kDa, 40 kDa and 60 kDa, and up to between 50 kDa and 60 kDa. The polymers used in the invention, particularly PEG, can be straight chain polymers or may possess a branched conformation.
  • In a further embodiment, the domain antibody construct according to the first aspect may be multimerised, as for example, hetero- or homodimers, hetero- or homotrimers, hetero- or homotetramers, or higher order hetero- or homomultimers. Multimerisation can increase the strength of antigen binding, wherein the strength of binding is related to the sum of the binding affinities of the multiple binding sites.
  • In a fifth aspect, the invention provides a pharmaceutical composition comprising an effective amount of the domain antibody construct according to the first aspect, together with a pharmaceutically acceptable carrier or diluent.
  • A “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like which are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like as well as combinations thereof. In many cases it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable substances such as minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers.
  • The composition may be in a variety of forms, including liquid, semi-solid and solid dosage forms, such as liquid solutions (eg inhalable, injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. Preferably, the composition is in the form of an injectable solution for immunization. The administration may be intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular.
  • Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. The proper fluidity of a solution can be maintained by for example, use of a coating such as lecithin and/or surfactants. Sterile injectable solutions can be prepared by incorporating the active compound (ie. domain antibody construct) in the required amount into an appropriate solvent with one or a combination of ingredients listed above, followed by filtered sterilisation.
  • The composition may also be formulated as a sterile powder for the preparation of sterile injectable solutions.
  • In certain embodiments the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Compatible polymers may be used such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid.
  • The composition may also be formulated for oral administration. In this embodiment, the domain antibody construct may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
  • Formulations that allow for pulmonary, rectal, transdermal, intrathecal and intraocular administration will be familiar to persons skilled in the art.
  • Supplementary active compounds can also be incorporated into the composition. The domain antibody construct may be co-formulated with and/or co-administered with one or more additional therapeutic agents eg. soluble TNF-α receptor or a chemical agent that inhibits human TNF-α production, or antibodies that bind other targets such as cytokines or cell surface molecules. Alternatively, it may be co-administered with a soluble immunochemical reagent such as protein A, C, G or L.
  • An effective amount may include a therapeutically effective amount or prophylactically effective amount of the domain antibody construct of the invention. A therapeutically effective amount refers to an amount effective at dosages and for periods of time necessary, to achieve the desired therapeutic result. A prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Because a prophylactic dose is administered to a subject prior to or at an earlier stage of disease, the prophylactically effective amount may be less than the therapeutically effective amount.
  • In a sixth aspect, the present invention provides for the use of the domain antibody construct according to the first aspect of the invention in a diagnostic application for detecting human TNF-α.
  • For example, the anti-human TNF-α domain antibody construct according to the invention can be used to detect human TNF-α for example in a biological sample, such as serum or plasma using a conventional immunoassay, such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. The anti-human TNF-α domain antibody construct according to the invention can be assayed in biological fluids by a competition immunoassay using recombinant human TNF-α standards labelled with a detectable substance and an unlabelled anti-human TNF-α antibody.
  • The anti-human TNF-α domain antibody construct according to the invention may also be used to detect TNF-α from species other than humans such as non-human primates including cynomolgus, chimpanzee, marmoset, rhesus and other species such as dog, rat, mouse, rabbit, cat, pig, bovine.
  • The anti-human TNF-α domain antibody construct according to the invention may also be used in cell culture applications where it is desired to inhibit TNF-α activity.
  • In a seventh aspect, the invention provides a method for treating a disorder characterised by human TNF-α activity in a human subject, comprising administering to the subject a pharmaceutical composition according to the second aspect of the invention.
  • A disorder characterised by human TNF-α activity is intended to include diseases and other disorders in which the presence of TNF-α in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor which contributes to a worsening of the disorder. Preferably, the disorder characterised by human TNF-α activity is selected from the group consisting of inflammation, inflammatory diseases, sepsis, including septic shock, endotoxic shock, gram negative sepsis and toxic shock syndrome; autoimmune disease, including rheumatoid arthritis, juvenile arthritis, rheumatoid spondylitis, ankylosing spondylitis, Sjögren's syndrome, osteoarthritis and gouty arthritis, allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis, psoriasis, pemphigoid and nephrotic syndrome; inflammatory conditions of the eye, including macular degeneration, uveitis, Behçet's disease; infectious disease, including fever and myalgias due to infection and cachexia secondary to infection; graft versus host disease; tumour growth or metastasis, hematologic malignancies; pulmonary disorders including asthma, adult respiratory distress syndrome, shock lung, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, pulmonary fibrosis and silicosis; inflammatory bowel disorders including Crohn's disease and ulcerative colitis; cardiac disorders, congestive heart failure; vascular disorders including Wegener's disease, giant cell arteritis; inflammatory bone disorders, central nervous system disorders such as Alzheimer's disease; peripheral nervous system disorders such as sciatica, hepatitis, coagulation disturbances, burns, reperfusion injury, endometrosis, keloid formation and scar tissue formation.
  • In a particularly preferred embodiment, the disorder characterised by human TNF-α activity is age-related macular degeneration. TNF-α is implicated in stimulating VEGF production and promoting neovascularisation in the eye (Oh-H et al., 1999 Investigative Ophthalmology & Visual Science 40:1891-98), and therefore inhibitors of TNF-α activity, such as the domain antibody constructs described herein, would be useful for therapy of angiogenesis-related ocular disorders including age-related macular degeneration.
  • Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
  • All publications mentioned in this specification are herein incorporated by reference. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of each claim of this application.
  • In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following non-limiting examples.
  • Example 1 Materials and Methods Isolation of New World Primate VL Genes
  • Marmoset (genus Callithrix, species unknown) and Owl monkey (Aotus trivirgatus) genomic DNA were obtained from the European Collection of Cell Cultures (ECACC), catalogue numbers 85011419 and 90110510 respectively. Marmoset DNA was derived from cell line B95-8 while Owl monkey DNA came from cell line OMK 637-69.
  • Degenerate primers based on human Vκ leader sequences and recombination signal sequences (RSS) were derived from Walter and Tomlinson, Antibody Engineering: A Practical Approach (1996). The primers used for amplification of germline Vκ DNA were as follows:
  • Primer VK1BL
    AATCKCAGGTKCCAGATG (SEQ ID No:13)
    Primer VK1BL35a
    GTTYRGGTKKGTAACACT (SEQ ID No:14)
    Primer VK1BL35b
    ATGMCTTGTWACACTGTG (SEQ ID No:15)
  • PCR (30 cycles) was performed using Taq polymerase with either primer pair VK1BLxVK1BL35a or VK1BLxVK1BL35b. There was overlap between the sequences cloned and the two primer sets used.
  • Genomic PCR products were cloned into Invitrogen's TOPO TA cloning kit (Cat No K4500-01) and sequenced with M13 Forward and pUC Reverse primers. Sequence was confirmed in forward and reverse directions. In order to further confirm key sequences were not subject to PCR errors, the PCR and cloning process was repeated twice for marmoset sequences. Nucleotide (SEQ ID Nos:16-26 and SEQ ID Nos:38-43) and amino acid (SEQ ID Nos:27-37 and SEQ ID Nos:44-49) are given in FIG. 3 (A-G). Marmoset sequences 1, 2 and 3 were confirmed. Sequences 4, 5, 6, 7 and 8 were seen only in the initial PCR. Sequences 9, 10 and 11 were seen only in the repeat (ie second) PCR and cloning.
  • Oligo Synthesis and Cloning into Acceptor Sequence
  • Four CDR sequences, namely AATKLQS (SEQ ID No:1) from Owl monkey sequence 1 (SEQ ID No:44), EASSLQS (SEQ ID No:2) from Owl monkey sequence 2 (SEQ ID No:45), EASKLQS (SEQ ID No:3) from Marmoset sequence 1 (SEQ ID No:27), and SASNLET (SEQ ID No:4) from Marmoset sequence 2 (SEQ ID No:28), were chosen from the amino acid sequences shown in FIG. 3 (A-G). Owl Monkey sequence 5, YASSLQS (SEQ ID No:56) was found to be identical to GI6176295 an Aotus nancymaae (Ma's night monkey) cDNA sequence, all other sequences were unique.
  • The acceptor variable region (anti-TNF domain antibody) sequence in the expression vector (Domantis proprietary vector) was digested (25 μg) sequentially with KpnI and SanDI which excises the majority of FR2 as well as CDR2 as indicated on the restriction digest map, FIG. 4. The vector was then gel purified to remove the excised wild-type FR2 and CDR2 sequence.
  • Oligo annealing was performed by incubating oligo pairs (500 pmol, based on sequences shown in FIG. 3 (A-G)) at 95° C. for 5 minutes followed by 65° C. for 5 minutes and then allowed to reach room temperature slowly on a hot block. Overlaps were then filled in during a Klenow reaction in the presence of dNTPs. Molecular cloning of the synthetic double-stranded DNA (derived by oligo annealing and end filling) into the acceptor variable region sequence was achieved using standard methods.
  • Affinity Maturation
  • The marmoset CDR-grafted dAb Compound 145 (SEQ ID No:7) was affinity matured by constructing 14 separate libraries, each a diversification of the sequence of SEQ ID No:7 at a single amino acid residue. The selected residues are shown bolded below.
  • DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS
    ASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF
    GQGTKVEIKR
  • The selection was based upon residues in CDR1 and CDR3 that are known to be diversified in the mature human Ig repertoire, and framework residues that have been observed to produce functional proteins after mutagenesis in related dAbs. For each of the selected residues, complimentary forward and reverse PCR primer pairs were designed with NKK degeneracy, and two initial PCR reactions were performed each with a single mutagenic primer and flanking primer. After clean-up, the two PCR products were annealed and then amplified using flanking primers alone (splicing by overlap extension of PCR; Lowman H. L. & Clackson T. (eds), Phage Display: A practical approach, Oxford University Press, Oxford, UK). Clones were initially screened by ELISA using solid-phase TNF, and positive clones were sequenced. dAb protein was purified from the best clones and evaluated for potency in receptor binding assays and L929 cytotoxicity assays. Compounds 100 (SEQ ID No:9) and 123 (SEQ ID No:8) were found to have improved TNF-neutralization relative to the parent dAb, Compound 145 (SEQ ID No:7).
  • Combination of the affinity-enhancing substitutions of Compounds 100 and 123, yielded an anti-TNF dAb with further improved potency in the L929 cytotoxicity assay (Compound 196; SEQ ID No:10).
  • Cell Culture
  • CHOK1SV cells (Lonza Biologics, UK), a suspension variant of CHOK1, were maintained in logarithmic growth phase in CD CHO media supplemented with 6 mM L-glutamine (Invitrogen Cat Nos. 10743-029 and 25030-081). Cultures were incubated at 36.5° C., 10% CO2 and shaking at 140 rpm. 24 hours before transfection cell number and viability was assessed by trypan blue exclusion (Sigma Cat No. T8154) on a haemocytometer. 8×106 viable cells were pelleted at 200×g for 5 minutes and resuspended in 8 ml of CM25 media (Lonza Biologics, UK) supplemented with 10% heat inactivated dialysed fetal calf serum (Invitrogen Cat No. 26400-044) and 6 mM L-glutamine. Cells were plated out at 500 per well in a 24 well plate and incubated at 36.5° C., 10% CO2.
  • 3 hours before transfection the media was replenished with a fresh aliquot of 500 CM25 media supplemented with 10% heat inactivated dialysed fetal calf serum and 6 mM L-Glutamine.
  • Expression Vectors
  • Gene sequences for Compound 112 (SEQ ID No:50) and Compound 170 (SEQ ID No:51) were optimized for mammalian cell expression and synthesized.
  • Compound 112
    (SEQ ID No: 50)
    GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGC
    GATAGAGTGACCATCACCTGCAGAGCCAGCCAGGCCATCGACAGCTAC
    CTGCACTGGTATCAGCAGAAGCCTGGCAAGGCCCCTAAGCTGCTGATC
    TACAGCGCCAGCAATCTGGAGACCGGCGTGCCTAGCAGATTCAGCGGC
    AGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCTGCCT
    GAGGATTTCGCCACCTACTACTGCCAGCAGGTGGTGTGGAGACCTTTC
    ACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGCGGGTGGAGCCCAAG
    AGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTG
    CTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACC
    CTGATGATCAGCAGAACCCCCGAGGTGACCTGCGTGGTGGTGGATGTG
    AGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTG
    GAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGC
    ACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTG
    AACGGCAAGGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCC
    CCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCC
    CAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAG
    GTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCC
    GTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACC
    CCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTG
    ACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGC
    GTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGC
    CTGTCCCCTGGCAAG
    Compound 170
    (SEQ ID No: 51)
    GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGC
    GATAGAGTGACCATCACCTGCAGAGCCAGCCAGGCCATCGACAGCTAC
    CTGCACTGGTATCAGCAGAAGCCTGGCAAGGCCCCTAAGCTGCTGATC
    TACAGCGCCAGCAATCTGGAGACCGGCGTGCCTAGCAGATTCAGCGGC
    AGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCTGCCT
    GAGGATTTCGCCACCTACTACTGCCAGCAGGTGGTGTGGAGACCTTTC
    ACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGCGGGTGGAGCCCAAG
    AGCAGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTG
    CTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACC
    CTGATGATCAGCAGAACCCCCGAGGTGACCTGCGTGGTGGTGGATGTG
    AGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTG
    GAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGC
    ACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTG
    AACGGCAAGGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCC
    CCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCC
    CAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAG
    GTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCC
    GTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACC
    CCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTG
    ACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGC
    GTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGC
    CTGTCCCCTGGCAAG 
  • Each sequence was flanked at the 5′ end with a Hind III site, a Kozak sequence (GCCACC; SEQ ID No:57) and a human IgG kappa leader sequence (amino acid sequence MSVPTQVLGLLLLWLTDARC; SEQ ID No:58). At the 3′ end two stop codons and an EcoR I site were added to each sequence. Following synthesis genes were provided cloned into a pCRScript vector (Stratagene) and were released by Hind III/EcoR I digestion in the appropriate restriction enzyme buffer (Roche Diagnostics Cat Nos. 10656313001, 10703737001 and 11417967001 respectively). The GS expression vector pEE12.4 (Lonza Biologics, UK) was similarly digested and dephosphorylated using calf intestinal alkaline phosphatase Roche Diagnostics Cat No. 10713023001). Each gene was ligated into the prepared pEE12.4 backbone using the LigaFast Rapid DNA Ligation System from Promega (Cat No. M8221). Ligations were then transformed into One Shot Top 10 chemically competent cells (Invtrogen Cat No. C4040-03) and positive colonies identified by standard techniques. Large quantities of the resulting vectors (pEE12.4-PNO621 and pEE12.4-PNO521-S114C) were prepared by midiprep of overnight cultures using QIAfilter midiprep columns (QIAgen Cat No. 12243). Vectors were prepared for transfection by precipitating 20 μg in 100% ethanol with 1/10 volume of 3 M sodium acetate (pH 5.2) (Sigma Cat Nos. E7023 and 52889 respectively). Following a wash in 70% ethanol, vectors were resuspended in 40 μl of T.E. pH 8.0 (Sigma Cat No. T9285) at a working concentration of 0.5 μg/μl.
  • Transfection
  • For each transfection 2 μl of Lipofectamine 2000 was added to 50 μl of Optimem I media (Invitrogen Cat Nos. 11668-027 and 31985-062) in a well of a 96 well plate. In a second well 1.6 μl of the expression vector (0.8 μg) was added to 50 μl of Optimem I media. Following a 5 minute room temperature incubation the contents of the two wells were mixed together and left for a further 20 minute incubation. Following this second incubation the whole transfection mixture was added to a well in the 24 well plate containing the CHOK1SV cells. Cells were incubated for at least 72 hours and supernatants harvested. Supernatants were centrifuged at 4,000×g for 5 minutes to pellet cell debris and were stored at −20° C. until expression of Compound 112 (SEQ ID No:59) and Compound 170 (SEQ ID No:11) was assayed by TNF ELISA.
  • Compound 112
    (SEQ ID No: 59)
    DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI
    YSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPF
    TFGQGTKVEIKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
    LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
    TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
    QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
    PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
    LSPGK 
  • TNF Elisa
  • Microtitre plates (e.g. Sarstedt 82.9923-148) were coated with a 1 μg/mL solution of human recombinant TNF-α (Peprotech Cat # 300-01A) in carbonate/bicarbonate coating buffer pH 9.6, 100 μL/well. After overnight incubation at 4° C., plates were washed 3 times with PBS (0.01 M, pH 7.2) with 0.05 % Tween 20, and 3 times with PBS. 200 μL blocking buffer (PBS with 1% BSA {bovine serum albumin, Sigma Cat #A-9647}) was added per well and incubated at 25° C. for 1 hour. Plates were washed, as above, and 100 μL volumes of sample or Compound 170 standards diluted in antibody diluent (PBS with 1% BSA and 0.05% Tween 20) were added per well. After 1 hour incubation at 25° C., plates were washed, as above, and 100 μL volumes of secondary antibody (peroxidase-conjugated goat anti-human immunoglobulins, Zymed, Cat # 81-7120) at 1:1000 dilution in antibody diluent were added per well. Plates were washed and 100 μL volumes of ABTS substrate (2,2′-Azino-bis(3-Ethylbenz-Thiazoline-6-Sulfonic acid) diammonium salt, Sigma Cat # A-1888, 0.5 mg/mL in citrate buffer pH 4.4, with 0.03% H2O2) were added per well. Substrate was developed for 30 minutes at room temperature and absorbance read at 405 nm (reference 620 nm). Sample concentrations were determined relative to the standard curve and were expressed relative to the mean concentration of Compound 112 expressed.
  • Results Inclusion of Truncated C H1
  • Inclusion of the truncated C H1 in the domain antibody construct results in a junction between the variable domain and hinge with higher homology to a conventional IgGi CH1-hinge junction (91.7%) than a junction lacking the truncated CH1 (83.3%; calculated using Align X on Vector NTI (Invitrogen) with a gap opening penalty of 1). Enhanced homology is likely to translate to increased resemblance to conventional immunoglobulin peptide sequences to which human patients should be immunologically tolerant, thereby reducing immunogenic potential.
  • Sequences:
  • Compound 170 variable region-truncated CH1-hinge
    junction:
    TKVEIKRVEPKS (SEQ ID NO: 65)
    IgG1 CH1-hinge junction (NCBI accession AAG00909):
    TKVDKRVEPKS (SEQ ID NO: 66)
    Compound 170 variable region-hinge junction
    (truncated C H1 absent):
    TKVEIKREPKS  (SEQ ID NO: 67)

    C H1 sequence is bolded as indicated.
    C H1 domain (SEQ ID No:60) obtained from NCBI protein database (http://www.ncbi.nlm.nih.gov) AAG00909:
  •   1 STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
     61 LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
    121 SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
    181 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
    241 TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
    301 QGNVFSCSVM HEALHNHYTQ KSLSLSPGK

    CH1-hinge junction is indicated in underline.
  • Neutralization of TNF-α-Induced Cytotoxicity
  • The ability of the domain antibody construct Compound 170 (SEQ ID No:11) to neutralize TNF-α-mediated cytotoxicity was assessed using a murine L929 cell viability assay. Serial dilutions of Compound 170 in RPMI medium with 10% foetal bovine serum (RPMI-FBS) were prepared in 50 μL volumes in flat bottomed 96 well plates. To each of these wells was added 50 μL recombinant human TNF-α (Strathmann Biotec, Hamburg, Germany) at a concentration of 360 pg/mL, followed by 2.5×104 L929 cells in 50 μL and 25 μL Actinomycin D at 40 μg/mL, all prepared in RPMI-FBS. Controls included wells with no TNF (for determination of 100% viability), no cells (0% viability) and a TNF-α standard curve ranging from 2 pg/mL to 4200 pg/mL. Culture plates were incubated in a 5% CO2 atmosphere at 37° C. for 20 hours, then for a further 3 hours after the addition of 25 μL 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)/phenazine ethosulfate (PES) (Promega CellTiter 96 AQueous One, Madison USA). Absorbance at 492 nm was determined against a reference wavelength of 630 nm and viability curves were plotted using average values calculated from triplicate test wells. The TNF-a-neutralizing ability of Compound 170 is indicated by increasing cell viability with increasing concentrations of Compound 170 (FIG. 6).
  • Neutralization of TNF-α Binding to Human p55 and p75 TNF Receptors
  • The ability of the domain antibody construct Compound 170 (SEQ ID No:11) to inhibit binding of TNF-α to human p55 and p75 TNF receptors was evaluated by receptor binding assays. Human p55 (RnD systems, Cat No: 372-RI) or p75 (RnD systems, Cat No: 762-R2) was coated onto Maxisorb plates (Nunc) at 0.1 μg/mL in carbonate coating buffer pH 9.2 by overnight incubation at 4° C. Serial half-log dilutions of Compound 170 ranging from 100 μg/mL down to 3.15 ng/mL (and a no Compound 170 ‘blank’ control) were prepared in antibody diluent (PBS pH 7.2, 0.05% Tween-20, 1% BSA) and were mixed with an equal volume of 60 ng/mL human TNF-α in antibody diluent. A blank containing no PN0621 and no TNF-α was also prepared to measure background binding. All mixtures were allowed to incubate for exactly 1 hour at room temperature with gentle agitation. During this incubation the coated plates were washed 3 times with PBS, 0.05% Tween-20 and then 3 times with PBS. The plates were then blocked with 200 μl/well of PBS, 1% BSA for 45 minutes at room temperature. Following washing of the plate, 100 μl of the Compound 170/TNF-α mixtures were added to triplicate wells for each concentration of Compound 170 tested along with addition of all the controls. The plate was then incubated at room temperature for 1 hour. Following washing of the plate, a biotinylated anti-human TNF-α antibody (RnD Systems, Cat No: BAF210) was added at 0.6 μg/mL in antibody diluent to each well and incubated for 1 hour at room temperature. Following washing a Streptavidin-HRP conjugate (Zymed, Cat No: 43-4323) was added at 1:2000 in antibody diluent and incubated at room temperature for 45 mins. Visualization was performed using TMB substrate (Invitrogen, Cat No: 00-2023) stopped with 1 M HCl after 4 minutes. Absorbance readings were then measured at 450 nm using a reference of 620 nm. Analysis was performed by calculating the average absorbance of the triplicates. The average of the non-specific binding (no TNF-a) was subtracted from each absorbance value.
  • The results are indicated in FIG. 7 and show that Compound 170 prevents the interaction of TNF-α with the human p55 or p75 TNF receptors.
  • Binding of Cell-Bound TNF-α
  • Analysis of binding to cell-bound (transmembrane) TNF-α was performed using an NS0 cell line, 27D4, stably transfected with a gene encoding human TNF-α protein lacking a TACE cleavage site, such that TNF-α remains cell membrane-associated because it cannot be cleaved. A similar cell line based on another murine myeloma (SP2/0) has been described (Scallon et al., (1995) Cytokine 7 251-259).
  • Flow cytometry analysis was performed on 5×105 viable 27D4 cells per sample with all steps performed at 4° C. or on ice. Cell pellets were resuspended with test (Compound 170; SEQ ID No:11) or irrelevant-specificity isotype-matched control (Sigma, Cat No: I5154) at 100 μg/ml in PBS containing 2% FBS, and incubated on ice for 1 hour. Two cell wash cycles were performed, each comprising, centrifugation for 10 minutes at 1000×g and resuspension of the cell pellet in PBS/2% FBS. Following another centrifugation step the cell pellet was resuspended in 100 μl secondary antibody conjugate (Anti-human Fc FITC conjugate, Sigma, Cat No: F9512) and incubated for 30 mins. The samples were then washed twice as described above and cell pellets resuspended in 500 μl PBS/2% FBS with 5 μg/mL propidium iodide (Sigma, Cat no: P4864). Fluorescent staining of cells was analysed on a Beckman Coulter Cell Lab Quanta flow cytometer and data was processed using WinMDI.
  • The results are indicated in FIG. 8, and show that Compound 170 staining of transmembrane TNF-α-expressing NS0 27D4 cells (solid black line) shows higher fluorescence intensity than irrelevant specificity isotype-matched control (grey fill).
  • Creation of High Compound 170-Expressing Cell Lines
  • Stable cell lines of CHOK1SV expressing Compound 170 (SEQ ID No:11) were created using the expression vector described in the Materials and Methods. Briefly 1×107 cells in logarithmic growth phase were electroporated in glutamine-free CDCHO protein-free media in the presence of 40 μg of linearised plasmid DNA. 24 hours post-transfection a selective pressure of 50 μM methionine sulphoximine (Sigma) was applied and resistant cells were allowed to form colonies in 96 well plates. When approaching confluence, single colonies were transferred to 24 well plates, T25 and then T75 flasks. Once over confluent in T75 flasks cell lines were progressed to culture in E125 Erlenmeyer flasks and adapted to suspension growth over 6 subcultures. Once adapted to suspension growth cell lines were cryopreserved in a freeze mix of 92.5% CDCHO media:7.5% DMSO.
  • Whilst cell lines were being expanded through the different well and flask sizes, a number of productivity assessments were performed in parallel to the progress of the cell lines to the next stage. Thus at the 24 well plate and E125 Erlenmeyer flask stages productivity assessments were performed. In each case cells were allowed to grow for 14 days and supernatants evaluated by the TNF ELISA method described in Example 1 for levels of Compound 170. Cell lines were ranked on the productivity and the highest 10 were selected for evaluation in a proprietary fed-batch productivity assessment at Lonza Biologics. Productivities obtained were between 700 mg/L and 3371 mg/L. A lead cell line with a productivity of 2724 mg/L was selected for evaluation in 10 L laboratory scale fermenters.
  • Four separate 10 L laboratory scale fermenters were run over 15 days with the lead cell line and a proprietary generic fed batch process based on the protein-free CDCHO media. The resulting mean productivity of the 4 fermentations was 4851 mg/L with the highest productivity being 4925 mg/L (the highest reported level of productivity previously reported by Lonza Biologics for a non clonal cell line in a 15 day fermentation is 3560 mg/L). The 10 L laboratory-scale fermenters used were designed to mimic the fermentation conditions found in larger scale fermenters up to 2000 L, hence the lead cell line is expected to be suitable for commercial scale manufacture. Indeed similar expression levels were observed in a 200 L fermenter.
  • Product harvested from the 4×10 L fermentations of the lead cell line expressing Compound 170 (SEQ ID No:11) was purified by Protein A affinity chromatography and analysed by SDS PAGE under both reducing and non-reducing conditions. As shown in FIG. 11, Compound 170 is expressed as a monomer of approximately 90 kDa. This monomer is composed of 2 subunits of approximately 40 kDa which are apparent in FIG. 12 when the SDS PAGE is run under reducing conditions. Since SDS PAGE is not suitable for exact sizing of proteins further analysis of the Compound 170 monomer has been performed. ESI-MS (electronspray ionisation mass spectrometry) has sized the Compound 170 monomer at 78.739 kDa. This is in agreement with the predicted molecular weight of 2 subunits (2×38.058=76.116 kDa) each of which also carry a bi-antennary core fucosylated glycan sugar structure.
  • Long Serum Half-Life in Non-Human Primates
  • Compound 170 (SEQ ID No:11) was administered subcutaneously to cynomolgus monkeys at doses of 0.5, 5 and 50 mg/kg, and blood samples were taken at 0.5, 1, 2, 6 and 24 hours then at 1 day, 2, 4, 7, 10 and 14 days. Analysis of these samples for quantitation of Compound 170 levels was performed using the anti-TNF ELISA method described in Example 1. Elimination half-life was determined by analysis of the levels of Compound 170 in these samples. At 0.5 mg/Kg an elimination half-life of 110.5±13.9 hours was calculated. At 5 mg/Kg and 50 mg/Kg elimination half-lives of 110.9±10.4 and 103.5±11.5 hours were calculated.
  • When Compound 170 was administered by intravenous route at 50 mg/Kg blood samples were taken at 10, 30 and 60 minutes, 4 and 24 hours, 2, 4, 7, 10 and 14 days. Analysis of these samples for quantitation of Compound 170 levels was performed using the anti-TNF ELISA method described in Example 1. Elimination half-life was determined by analysis of the levels of Compound 170 in these samples. Following 50 mg/Kg intravenous administration an elimination half-life of 109.6±10.7 hours was calculated.
  • Favorable Safety Profile
  • Compound 170 (SEQ ID No:11) manufactured to GMP standards was evaluated in animal safety and toxicology studies.
  • Single Dose Safety
  • Different monkeys administered single doses of Compound 170 at 0.5, 5 and 50 mg/kg by subcutaneous or intravenous route of administration showed no effects related to their treatment with Compound 170. In these studies microscopic examination of a range of organs was undertaken and no effects were observed.
  • Escalating Dose and Repeat Dose Safety
  • Starting with a dose of 0.5 mg/kg given either subcutaneously or intravenously escalating doses up to 50 mg/kg were administered to cynomolgus monkeys every 7 days. Animals were assessed for a wide range of physiological and behavioural parameters including haematology, clinical chemistry, body and organ weight and macroscopic inspection of organs following necropsy. Throughout these studies no adverse reactions to the treatment with Compound 170 were reported. Following the conclusion of the dose escalation phase of studies those animals which received the escalating dose subcutaneously were administered with a further 4 doses of 50 mg/kg over a further 4 week period. Again no effects, across the wide range of parameters, related to the treatment with Compound 170 were observed.
  • Cardiovascular Safety
  • The cardiovascular safety of Compound 170 at 50 mg/kg was evaluated in cynomolgus monkeys fitted with radio-telemetry monitors. These monitors report a range of respiratory and cardiovascular parameters directly from the conscious monkeys. Following dosing with Compound 170 no adverse treatment-related clinical observations were reported.
  • Bacterial Expression
  • Compound 170 (SEQ ID No:11) in preceding examples was produced in mammalian expression systems. Functional Compound 170 was also produced using a bacterial expression system.
  • The amino acid sequence for Compound 170 minus the signal sequence was back-translated and optimized by GeneOptimizer™ for E. coli expression and synthesized de novo at GeneArt GmbH. The synthesized gene was subcloned into the pBAD gIII/His-tagged expression vector (Invitrogen) via NcoI and HindIII restriction sites (Roche) generating a vector ready for bacterial expression. TOP10 cells (Invitrogen) were transformed with the vector by the heat shock method and glycerol stocks of single colonies generated. Induction conditions were 0.002% arabinose (Sigma; final concentration) and 4 hr induction period. Compound 170 protein samples were generated using the osmotic shock method as detailed in the pBAD bacterial expression system manual (Invitrogen). The BCA assay (Pierce) was used to determine the total protein concentration of the samples. Bacterially-expressed Compound 170 was assayed for binding to TNF-α in an ELISA as described in Example 1.
  • FIG. 9 shows that Compound 170 produced in a bacterial system retained binding to TNF-α in an ELISA assay.
  • The DNA sequence for bacterial expression of Compound 170 is as follows:
  • (SEQ ID No: 61)
    ATGGCGAGCACCGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC
    GCGAGCGTGGGTGATCGTGTGACCATTACCTGCCGTGCGAGCCAGGCG
    ATTGATAGCTATCTGCATTGGTATCAGCAGAAACCGGGCAAAGCGCCG
    AAACTGCTGATTTATAGCGCGAGCAACCTGGAAACCGGCGTGCCGAGC
    CGTTTTAGCGGCAGCGGTAGCGGCACCGATTTTACCCTGACCATTAGC
    AGCCTGCTGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGGTGGTG
    TGGCGTCCGTTTACCTTTGGCCAGGGCACCAAAGTGGAAATTAAACGC
    GTGGAACCGAAAAGCAGCGATAAAACCCACACGTGCCCGCCGTGTCCG
    GCGCCGGAACTGCTGGGTGGCCCGAGCGTGTTTCTGTTTCCGCCGAAA
    CCGAAAGATACCCTGATGATTAGCCGTACCCCGGAAGTGACCTGCGTG
    GTGGTGGATGTGAGCCATGAAGATCCGGAAGTGAAATTCAACTGGTAT
    GTGGATGGCGTGGAAGTGCATAACGCGAAAACCAAACCGCGTGAAGAA
    CAGTATAACAGCACCTATCGTGTGGTGAGCGTGCTGACCGTGCTGCAT
    CAGGATTGGCTGAACGGCAAAGAATACAAATGCAAAGTGTCTAACAAA
    GCGCTGCCGGCGCCGATTGAAAAAACCATCAGCAAAGCGAAAGGCCAG
    CCGCGTGAACCGCAGGTGTATACCCTGCCGCCGAGCCGTGATGAACTG
    ACCAAAAACCAGGTGAGCCTGACCTGCCTGGTGAAAGGCTTTTATCCG
    AGCGATATTGCGGTGGAATGGGAAAGCAACGGCCAGCCGGAAAACAAC
    TATAAAACCACCCCGCCGGTGCTGGATAGCGATGGCAGCTTTTTCCTG
    TATAGCAAACTGACCGTGGATAAAAGCCGTTGGCAGCAGGGCAACGTG
    TTTAGCTGCAGCGTGATGCATGAAGCGCTGCATAACCATTATACCCAG
    AAAAGCCTGAGCCTGAGCCCGGGTAAAGCGGCGGCG
  • The amino acid sequence encoded by SEQ ID No:61 is as follows:
  • (SEQ ID NO: 62)
    MASTDIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAP
    KLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVV
    WRPFTFGQGTKVEIKRVEPKSSDKTHTCPPCPAPELLGGPSVFLFPPK
    PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
    QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
    PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
    YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
    KSLSLSPGKAAAVDHHHHHH
  • In Vivo Efficacy of Compound 170 in a Human TNF-Mediated Murine Arthritis Model
  • The human TNF transgenic mouse line, Tg197, shows deregulated TNF expression and develops chronic inflammatory polyarthritis (Keffer, J. et. al. (1991) Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO Journal 10:4025-31). Administration of Compound 170 (SEQ ID No:11) prevented the development of arthritis and associated weight loss in these mice (FIGS. 10A & B). Groups of 8 heterozygous Tg197 (each containing 4 males and 4 females) were treated with twice weekly intraperitoneal injections of Compound 170 and irrelevant specificity control human IgG1 (palivizumab {Synagis®}, MedImmune/Abbott) in PBS, both at 10 mg/kg. Treatment commenced when mice were 3 weeks of age. At weekly intervals, mice were weighed and scored (arthritic score) based on macroscopic ankle morphology (swelling, distortion and degree of movement).
  • Substitution of Cys at Position 114 in Compound 112 Results in Increased Protein Expression
  • Compound 112 (SEQ ID No: 59) is a modification of Compound 170 (SEQ ID No:11) which contains a cysteine residue at position 114 instead of a serine residue which is present in this position in Compound 170. The effect of substituting cysteine 114 for serine on protein expression was evaluated by comparison with Compound 170. Multiple cultures of host cells transfected with gene constructs for Compound 112 and 170 were assayed for protein expression by ELISA with solid phase TNF as set out in Materials and Methods. The results are set out in FIG. 11.
  • It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims (21)

1. A domain antibody construct which binds to human TNF-α, the construct comprising:
(a) a domain antibody (dAb) which binds to human TNF-α;
(b) a modified hinge region sequence;
(c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues,
wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
2. The domain antibody construct according to claim 1 wherein the human or primate heavy chain constant region sequence having a truncated CH1 domain comprises not more than 10 residues.
3. The domain antibody construct according to claim 2 wherein the human or primate heavy chain constant region sequence having a truncated CH1 domain comprises not more than 5 residues.
4. The domain antibody construct according to claim 3 wherein the human or primate heavy chain constant region sequence having a truncated CH1 domain comprises not more than a single residue.
5. The domain antibody construct according to claim 1 wherein the sequence of the CH1 domain and the hinge region is XEPKSZDKTHTCPPCPA (SEQ ID No: 64) wherein X is valine, leucine or isoleucine and Z is absent or an amino acid other than cysteine.
6. The domain antibody construct according to claim 5 wherein X is valine and Z is serine.
7. The domain antibody construct according to claim 1 wherein the dAb comprises an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate wherein the CDR is selected from the group consisting of AATKLQS (SEQ ID No:1), EASSLQS (SEQ ID No:2), EASKLQS (SEQ ID No:3), and SASNLET (SEQ ID No:4).
8. The domain antibody construct according to claim 7 wherein the CDR is CDR2.
9. The domain antibody construct according to claim 1 wherein the domain antibody has a sequence selected from the group consisting of:
(SEQ ID No: 7) DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKWYS ASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPFTF GQGTKVEIKR; (SEQ ID No: 8) DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI YSASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPF TFGQGTKVEIKR; (SEQ ID No: 9) DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKLLI YSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPF TFGQGTKVEIKR; (SEQ ID No: 10) DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLI YSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPF TFGQGTKVEIKR; (SEQ ID No: 52) DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKPPKLLI YSASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVVWRPF TFGQGTKVEIKR; (SEQ ID No: 53) DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKLLI YSASNLETGVPSRFSGRGSGTDFTLTISSLQPEDFATYYCQQVVWRPF TFGQGTKVEIKR; (SEQ ID No: 54)  DIQMTQSPSSLSASVGDRVTITCRASQSIDSYLHWYQQKPGKAPKLLI YSASNLETGVPSRFSGSGSGTDFTLTISSLVPEDFATYYCQQVVWRPF TFGQGTKVEIKR; and
a sequence at least 95% identical to one of these sequences.
10. The domain antibody construct according to claim 1 wherein the cysteine residue within the hinge region which normally facilitates disulfide bond formation between heavy and light antibody chains is substituted with a serine residue.
11. The domain antibody construct according to claim 1 wherein the hinge region comprises the sequence EPKSSDKTHTCPPCPA (SEQ ID No:12).
12-20. (canceled)
21. The domain antibody construct according to claim 1 wherein the amino acid sequence is at least 60% identical to the sequence set forth in SEQ ID No:11.
22-29. (canceled)
30. A dimeric domain antibody construct which binds to human TNF-α wherein the dimer consists of two domain antibody constructs according to claim 1.
31. The dimeric domain antibody construct according to claim 30 wherein the dimeric domain antibody construct is a homodimer.
32. The dimeric domain antibody construct according to claim 31 wherein the domain antibody constructs making up the homodimer comprises an amino acid sequence which is at least 60% identical to the sequence set forth in SEQ ID No:11.
33-50. (canceled)
51. A pharmaceutical composition comprising an effective amount of a domain antibody construct according to claim 1, together with a pharmaceutically acceptable carrier or diluent.
52. A pharmaceutical composition comprising an effective amount of a dimeric domain antibody construct according to claim 30, together with a pharmaceutically acceptable carrier or diluent.
53-59. (canceled)
US12/831,874 2006-02-01 2010-07-07 Domain antibody construct Abandoned US20110044979A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/831,874 US20110044979A1 (en) 2006-02-01 2010-07-07 Domain antibody construct

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2006900456A AU2006900456A0 (en) 2006-02-01 Domain antibody construct
AU2006900456 2006-02-01
US81750706P 2006-06-28 2006-06-28
US11/670,261 US7846439B2 (en) 2006-02-01 2007-02-01 Domain antibody construct
US12/831,874 US20110044979A1 (en) 2006-02-01 2010-07-07 Domain antibody construct

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/670,261 Continuation US7846439B2 (en) 2006-02-01 2007-02-01 Domain antibody construct

Publications (1)

Publication Number Publication Date
US20110044979A1 true US20110044979A1 (en) 2011-02-24

Family

ID=45220168

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/670,261 Expired - Fee Related US7846439B2 (en) 2006-02-01 2007-02-01 Domain antibody construct
US12/831,874 Abandoned US20110044979A1 (en) 2006-02-01 2010-07-07 Domain antibody construct

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/670,261 Expired - Fee Related US7846439B2 (en) 2006-02-01 2007-02-01 Domain antibody construct

Country Status (12)

Country Link
US (2) US7846439B2 (en)
EP (1) EP1987064A4 (en)
JP (2) JP5259423B2 (en)
KR (1) KR20090039666A (en)
CN (2) CN101400703B (en)
AU (1) AU2007211829C9 (en)
BR (1) BRPI0707425A2 (en)
CA (1) CA2640661A1 (en)
EA (1) EA017417B1 (en)
MX (1) MX2008009792A (en)
NZ (1) NZ569988A (en)
WO (1) WO2007087673A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006281980A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
EP1969010A4 (en) * 2005-12-20 2009-07-22 Peptech Ltd Anti-inflammatory dab
WO2007087673A1 (en) 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
EP2036980A1 (en) * 2007-09-14 2009-03-18 Gruber, Jens Down regulation of gene expression using virus-like particles charged with nucleic acid
US9181327B2 (en) 2008-01-07 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-HIV domain antibodies and method of making and using same
BRPI0914005A2 (en) * 2008-07-02 2015-11-17 Emergent Product Dev Seattle multi-target tnf-alpha antagonist proteins
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
CA2744055A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
IT1394281B1 (en) * 2009-01-19 2012-06-06 Zardi PROCESS FOR THE PRODUCTION OF POLYVALENT AND POLYSPECIFIC MELTING PROTEINS USING AS A STRUCTURE CARRYING OUT THE UTEROGLOBIN AND PRODUCTS OBTAINED SO.
EP2419448A1 (en) * 2009-04-16 2012-02-22 Abbott Biotherapeutics Corp. Anti-tnf- antibodies and their uses
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
CN104045715B (en) * 2013-03-15 2018-05-01 兰州大学 The preparation and application of Dimerized fusion protein
MX2018001566A (en) 2015-08-07 2019-04-25 Imaginab Inc Antigen binding constructs to target molecules.
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5585089A (en) * 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5612460A (en) * 1989-04-19 1997-03-18 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5627052A (en) * 1990-08-02 1997-05-06 B.R. Centre, Ltd. Methods for the production of proteins with a desired function
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5969108A (en) * 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
US20030039649A1 (en) * 2001-07-12 2003-02-27 Jefferson Foote Super humanized antibodies
US20030118592A1 (en) * 2001-01-17 2003-06-26 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030143682A1 (en) * 2000-11-07 2003-07-31 Nicolaides Nicholas C. Antibodies and methods for generating genetically altered antibodies with high affinity
US20030199679A1 (en) * 1990-12-21 2003-10-23 Adair John Robert Recombinant antibodies specific for TNF-alpha
US20030215427A1 (en) * 2001-04-11 2003-11-20 Michael Jensen CE7-specific redirected immune cells
US20030232971A1 (en) * 1989-08-07 2003-12-18 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20040101905A1 (en) * 2000-12-01 2004-05-27 Brekke Ole Henrik Andre Product
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US6821505B2 (en) * 1997-03-03 2004-11-23 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US20050118643A1 (en) * 2003-07-18 2005-06-02 Burgess Teresa L. Specific binding agents to hepatocyte growth factor
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060024308A1 (en) * 2004-07-06 2006-02-02 Roberto Crea High affinity anti-TNF-alpha antibodies and method
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060038027A1 (en) * 2004-03-15 2006-02-23 Boston Scientific Scimed, Inc. Apparatus and method for fine bore orifice spray coating of medical devices and pre-filming atomization
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060083747A1 (en) * 2002-12-27 2006-04-20 Domantis Limited Fc fusion
US20060210526A1 (en) * 2003-07-11 2006-09-21 Brocchini Stephen J Conjugated biological molecules and their preparation
US20070003549A1 (en) * 2004-08-24 2007-01-04 Olga Ignatovich Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20070111281A1 (en) * 2005-05-09 2007-05-17 Glycart Biotechnology Ag Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
US20070202105A1 (en) * 2006-02-01 2007-08-30 Peptech Limited Domain antibody construct
US20070269449A1 (en) * 2003-03-26 2007-11-22 Apogenix Gmbh Fc Fusion Proteins
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
US20080095767A1 (en) * 2005-08-15 2008-04-24 Peptech Limited Engineered antibodies with new world primate framework regions
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
US20080227958A1 (en) * 2006-04-14 2008-09-18 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
US20080241166A1 (en) * 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
US20080260738A1 (en) * 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20090075338A1 (en) * 2004-03-08 2009-03-19 Zymogenetics, Inc Dimeric fusion proteins and materials and methods for producing them
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US20090221803A1 (en) * 2005-04-26 2009-09-03 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US20090226428A1 (en) * 2005-12-20 2009-09-10 Arana Therapeutic Limited Anti-inflammatory dab
US20100125130A1 (en) * 1989-08-07 2010-05-20 Deborah Ann Rathjen Tumour necrosis factor binding ligands

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3095168B2 (en) 1988-02-05 2000-10-03 エル. モリソン,シェリー Antibodies with domain-denaturing constants
ATE151110T1 (en) 1988-09-02 1997-04-15 Protein Eng Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
JPH06508511A (en) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド Method for producing specific binding pair members
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
SK285046B6 (en) 1991-07-25 2006-05-04 Idec Pharmaceuticals Corporation Chimeric antibody, that specifically binds to human antigen, pharmaceutical composition in which the antibody is comprised, process of its production and using of it
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
DE69621940T2 (en) 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000003I2 (en) 1996-02-09 2007-03-29 Abbott Biotech Ltd Human antibodies which bind to human TNFalpha
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
ES2373110T3 (en) 1997-01-21 2012-01-31 The General Hospital Corporation SELECTION OF PROTEINS USING ARN-PROTEIN FUSIONS.
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
WO1998049286A2 (en) 1997-05-01 1998-11-05 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
IES80929B2 (en) 1997-11-26 1999-06-30 Donal Richard Mcgoey Filter with form-retaining stabilizing means
JP2002522063A (en) * 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド Generation of modified molecules with increased serum half-life
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
ATE338124T1 (en) 2000-11-07 2006-09-15 Hope City CD19-SPECIFIC TARGETED IMMUNE CELLS
DE60328195D1 (en) 2002-03-29 2009-08-13 Schering Corp HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
KR101103218B1 (en) * 2002-11-08 2012-01-05 아블린쓰 엔.브이. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050136428A1 (en) 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
PT1639011E (en) 2003-06-30 2009-01-20 Domantis Ltd Pegylated single domain antibodies (dab)
AU2004290016A1 (en) 2003-11-07 2005-05-26 Amgen Inc. Monkey immunoglobulin sequences
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7678371B2 (en) 2005-03-04 2010-03-16 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
ZA200802247B (en) 2005-08-15 2009-08-26 Arana Therapeutics Ltd Chimeric antibodies with new world primate regions

Patent Citations (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5837500A (en) * 1988-09-02 1998-11-17 Dyax, Corp. Directed evolution of novel binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5403484A (en) * 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
US5571698A (en) * 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5585089A (en) * 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5612460A (en) * 1989-04-19 1997-03-18 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US20100125130A1 (en) * 1989-08-07 2010-05-20 Deborah Ann Rathjen Tumour necrosis factor binding ligands
US20030232971A1 (en) * 1989-08-07 2003-12-18 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5580717A (en) * 1990-05-01 1996-12-03 Affymax Technologies N.V. Recombinant library screening methods
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5969108A (en) * 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5627052A (en) * 1990-08-02 1997-05-06 B.R. Centre, Ltd. Methods for the production of proteins with a desired function
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
US20030199679A1 (en) * 1990-12-21 2003-10-23 Adair John Robert Recombinant antibodies specific for TNF-alpha
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6821505B2 (en) * 1997-03-03 2004-11-23 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US20030143682A1 (en) * 2000-11-07 2003-07-31 Nicolaides Nicholas C. Antibodies and methods for generating genetically altered antibodies with high affinity
US20040101905A1 (en) * 2000-12-01 2004-05-27 Brekke Ole Henrik Andre Product
US20030118592A1 (en) * 2001-01-17 2003-06-26 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030215427A1 (en) * 2001-04-11 2003-11-20 Michael Jensen CE7-specific redirected immune cells
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20090258012A1 (en) * 2001-06-28 2009-10-15 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20030039649A1 (en) * 2001-07-12 2003-02-27 Jefferson Foote Super humanized antibodies
US20080241166A1 (en) * 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060083747A1 (en) * 2002-12-27 2006-04-20 Domantis Limited Fc fusion
US20070269449A1 (en) * 2003-03-26 2007-11-22 Apogenix Gmbh Fc Fusion Proteins
US20060210526A1 (en) * 2003-07-11 2006-09-21 Brocchini Stephen J Conjugated biological molecules and their preparation
US20050118643A1 (en) * 2003-07-18 2005-06-02 Burgess Teresa L. Specific binding agents to hepatocyte growth factor
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20090075338A1 (en) * 2004-03-08 2009-03-19 Zymogenetics, Inc Dimeric fusion proteins and materials and methods for producing them
US20060038027A1 (en) * 2004-03-15 2006-02-23 Boston Scientific Scimed, Inc. Apparatus and method for fine bore orifice spray coating of medical devices and pre-filming atomization
US20060024308A1 (en) * 2004-07-06 2006-02-02 Roberto Crea High affinity anti-TNF-alpha antibodies and method
US20070003549A1 (en) * 2004-08-24 2007-01-04 Olga Ignatovich Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20090081233A1 (en) * 2004-08-24 2009-03-26 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20090221803A1 (en) * 2005-04-26 2009-09-03 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US20070111281A1 (en) * 2005-05-09 2007-05-17 Glycart Biotechnology Ag Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
US20080095767A1 (en) * 2005-08-15 2008-04-24 Peptech Limited Engineered antibodies with new world primate framework regions
US20090286962A1 (en) * 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
US8263076B2 (en) * 2005-12-20 2012-09-11 Cephalon Australia Pty Ltd. Anti-inflammatory dAb
US20090226428A1 (en) * 2005-12-20 2009-09-10 Arana Therapeutic Limited Anti-inflammatory dab
US7846439B2 (en) * 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
US20070202105A1 (en) * 2006-02-01 2007-08-30 Peptech Limited Domain antibody construct
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
US20080227958A1 (en) * 2006-04-14 2008-09-18 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
US20080255343A1 (en) * 2006-12-08 2008-10-16 Arana Therapeutics Limited Chimeric antibodies
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
US20080260738A1 (en) * 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs

Also Published As

Publication number Publication date
EA200870208A1 (en) 2009-02-27
CN103232540A (en) 2013-08-07
BRPI0707425A2 (en) 2011-05-03
US20070202105A1 (en) 2007-08-30
JP2013059338A (en) 2013-04-04
JP5259423B2 (en) 2013-08-07
EA017417B1 (en) 2012-12-28
AU2007211829A1 (en) 2007-08-09
AU2007211829C1 (en) 2013-05-23
EP1987064A1 (en) 2008-11-05
CA2640661A1 (en) 2007-08-09
JP2009525031A (en) 2009-07-09
NZ569988A (en) 2011-09-30
US7846439B2 (en) 2010-12-07
MX2008009792A (en) 2008-09-01
AU2007211829C9 (en) 2013-07-11
KR20090039666A (en) 2009-04-22
AU2007211829B2 (en) 2012-11-08
AU2007211829C8 (en) 2013-06-27
WO2007087673A1 (en) 2007-08-09
CN101400703B (en) 2013-05-08
CN101400703A (en) 2009-04-01
EP1987064A4 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
US7846439B2 (en) Domain antibody construct
JP2009525031A5 (en)
US7981414B2 (en) Anti-inflammatory dAb
ES2387312T3 (en) Stabilized human IgG4 antibodies
US20080095767A1 (en) Engineered antibodies with new world primate framework regions
EP3216804A2 (en) Anti-cd25 antibodies and their uses
US20080255343A1 (en) Chimeric antibodies
AU2006281981A1 (en) Chimeric antibodies with new world primate regions
WO2008092209A1 (en) Protein construct with improved properties
NZ569405A (en) Anti-inflammatory domain antibody binding to TNF-alpha
MX2008008029A (en) Anti-inflammatory dab
MX2008002162A (en) Engineered antibodies with new world primate framework regions

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION